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Abstract 
 
Electrical coupling between mammalian cardiac myocytes allows orderly spread of 
excitation and is mediated by gap junction (GJ) channels composed of connexin (Cx) 
proteins. In normal myocardium, gap junctions within the intercalated disc allow 
intercellular transfer of ions and represent low resistance pathways for electrical 
propagation.  
 
GJ remodelling describes either a change in connexin expression and/or redistribution 
toward the lateral cell borders. This remodelling is thought to play a crucial role in 
arrhythmogenesis. 
 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. AF becomes 
more persistent over time (“AF begets AF”). This self perpetuating nature of AF is 
poorly understood and may be associated with GJ remodelling. 
 
The aim of this thesis was to characterise the GJ structural remodelling that occurs 
alongside electrical changes in AF and to investigate the role of gap junction modulation 
on changes in electrical propagation, using animal and cell models. 
 
The findings of the in vivo goat burst-pacing model suggest that late AF-induced electrical 
remodelling occurs with a similar time course to connexin remodelling.  These 
consistencies in the timescale of remodelling suggest that structural GJ remodelling is a 
likely determinant of the development of persistent AF. Although electrical remodelling 
6 
is unaffected by the angiotensin receptor blocker, candesartan, its administration does 
attenuate GJ remodelling.  
 
HL-1 is a cardiac muscle cell line with a phenotype that is similar to atrial myocytes, 
particularly in connexin expression. Rapid pacing did not induce a change in the pattern 
of activation. GJ uncoupling with carbenoxolone resulted in reversible slowing of 
conduction and could be used as a method of modifying conduction.  
 
This thesis provides an insight into the role of gap junctions in conduction propagation 
both in the intact myocardium in an animal model of AF and in an in vitro cell model. 
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Chapter 1: Introduction 
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“As to the heart: it moves itself, and doth never stop, except it be for eternity” 
   Leonardo DaVinci 
 
1.1 Function of the heart 
 
The heart is a pump. Its function is to circulate blood around the body. Cardiac myocytes 
have the unique property of contracting in synchrony, allowing the heart to provide 
repeated coordinated contractions of the atria and then the ventricles via the orderly 
spread of the wave of excitation and contraction from one myocyte to the next. To act in 
this way cardiac myocytes must be electrically coupled. Cell-to-cell coupling between 
mammalian cardiac myocytes is mediated by gap junction channels composed of proteins 
belonging to the Connexin (Cx) family. In healthy myocardium the majority of gap 
junction channels are present within the intercalated disc. (Severs 1990).  
 
1.2 Intercalated disc 
 
The intercalated disc is a specific area of the plasma membrane that mediates 
electromechanical coupling of the myocytes. They occur at the blunt end of each 
myocyte, joining it to multiple neighbouring cells. Three cell junction types lie within this 
structure: gap junctions, fascia adherens, and desmosomes as shown in Figure 1.1. Fascia 
adherens and desmosomes are required for cell adhesion. Fascia adherens are anchoring 
sites for actin and desmosomes bind intermediate filaments (Severs 1990). Gap junctions 
allow small molecules and ions to pass directly between the cytoplasms of two adjacent 
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cells, therefore, represent a low resistance pathway for intercellular signalling and action 
potential propagation (Severs 1990). 
 
 
 
Figure 1.1 Thin-section electron micrograph illustrating the three types of cell junction of 
the intercalated disc  
From Severs The Cardiac Muscle Cell (Severs 2000). Gap junctions are recognised where the adjacent plasma 
membrane profiles run in close contact, separated by a gap of 2nm. The fascia adherens and the desmosome are 
characterised by a much wider intermembrane space (25 nm) and by prominent electron-dense membrane associated 
proteins.  
 
1.2.1 Gap junction and connexin structure  
 
Thin section electron microscopy shows the gap junctions to be zones of near contact 
between adjacent plasma membranes separated by a gap of 2-3nm (Severs 2001) as seen 
in Figure 1.1. This specific distance of the gap gives rise to the name „„gap junction”.   
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Each gap junctional channel is constructed from two hemichannels, termed connexons, 
containing six rod-like protein subunits (connexins) oriented perpendicular to the 
membrane (Unwin & Zampighi 1980, Unwin & Ennis 1984) (Figure 1.2). The two 
hemichannels dock in the extracellular space to form a functional channel with a central 
pore for passage of ions and small molecules. 
 
 
Figure 1.2 A diagrammatic representation of gap junction channels.  
Two adjacent cells each contribute a hemi-channel (connexon) to form the complete gap junction channel. Each 
hemichannel is itself formed by six protein subunits, called connexins. 
 
 
In 1974 Goodenough first proposed the name connexins for the proteins of gap 
junctions, reflecting their role in connecting adjacent cells (Goodenough 1974). A 
topological model of rat liver gap junctions of Cx32 was first proposed by Zimmer 
(Zimmer et al. 1987). This has remained largely unchanged.  
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Each connexin protein possesses four hydrophobic transmembranal regions termed M1 
to M4 (from N to C terminus). These hydrophobic regions form a hexameric structure. 
Each connexin contributes two loops (referred to as E1 and E2) to the extracellular 
domain and these are thought to contribute to the interaction between adjacent cells 
(Kumar & Gilula 1996) (Figure 1.3).  
 
 
Figure 1.3 Model of a connexin protein.  
From Kumar and Gilula (Kumar & Gilula 1996). There are transmembranal regions M1-M4 and two 
extracellular loops E1and E2. 
 
The connexin gene family is diverse with 21 identified members in the sequenced human 
genome (Sohl & Willecke 2003). Connexins are most commonly named according to 
their molecular weights in kDa. The three main cardiac connexins are Cx43, Cx40 and 
Cx45. Different cardiac tissue have distinctive connexin expression as shown in Figure 
1.4. The biophysical properties of different combinations of connexins may be a 
functional determinant of impulse propagation (Desplantez et al. 2007). Cx43 is found 
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throughout the heart, with the exception of parts of the conduction system (Gros & 
Jongsma 1996). Cx40 is expressed in atrial tissue (with the exception of the rat heart) and 
in the proximal and distal conduction system (with the exception of the guinea pig heart) 
and the Purkinje fibres (Gros et al. 1994, van Kempen et al. 1995). Cx45 expression is 
limited to nodal tissues and the conduction system (Coppen et al. 1999) except in humans 
(Davis et al. 1995, Vozzi et al. 1999).  
 
 
 
 
Figure 1.4 Summary of the expression patterns of connexins in mammalian myocardium. 
From Severs (Severs et al. 2008). The distribution of connexins varies through the heart and expression is thought 
to be a functional determinant of impulse propagation. 
 
1.2.2 Combinations of connexins in connexons 
 
Theoretically, a connexon hemichannel in a cardiac gap junction can be composed of any 
combination of six Cx43, Cx40 or Cx45 subunits and the two hemichannels may be 
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composed from any two combinations of hemichannels. Therefore, a hemichannel can 
be predicted to be either homomeric (all six subunits are the same) or heteromeric (two 
or more different subunits). This can give rise to a variety of full channel types, including 
homotypic if all 12 subunits are identical, heterotypic if each two connexon contain 
identical subunits, monoheteromeric when a homomeric connexon docks with a 
heteromeric connexon and bi-heteromeric when two heteromeric connexons dock 
together (Moreno 2004) as represented in figure 1.5. Some channel combinations may be 
non-functional. Cells co-expressing Cx43 and Cx40 show similar electrophysiological 
properties to homomeric Cx43 and Cx40 hemichannels suggesting incompatibility for 
heteromeric mixing (Valiunas et al. 2001). This is of importance in the atria where both 
Cx43 and Cx40 are expressed as some combinations will be non-functional. 
 
 
 
Figure 1.5 Theoretical combinations of connexins  
From (Moreno 2004). Connexin45 and Cx43 are represented in white and grey, respectively.  
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1.3 Gap junction biophysical properties  
 
1.3.1 Channel gating 
 
Gap junction channels can occur in three states: open, where there is maximal 
conductance; residual, associated with voltage gating, but not with chemical gating; and 
closed, where there is non-conduction (Moreno 2004). Voltage gating involves rapid 
transjunctional voltage-sensitive transitions between a primary open state and one or 
more subconductance states, but not to a fully closed state which affects macroscopic 
junctional conductance. However, a change in single channel currents dependent on 
junctional voltage which involves slow transitions between fully open and closed states 
has also been seen. This gating in termed “loop” gating as it has been hypothesised to be 
initiated by contact between the extracellular loops of connexons. Direct chemical gating 
involves modulation by binding of ligands. Studies have shown that chemical gating may 
include the effects of intracellular pH, n-alkyl alcohols, fatty acids and calcium ions 
(Harris 2001). The state of the gap junctional channels can affect action potential 
propagation because a change in ion flow between adjacent myocytes may modulate 
conduction velocity (Desplantez et al. 2007).  
 
1.3.2 Phosphorylation  
 
A change in phosphorylation state is a mechanism of functional modulation for many 
proteins. Connexin phosphorylation states can lead to a stabilization between open and 
closed states (Levitan 1999). For Cx43, at least three distinct bands can be resolved by 
Western blot. The fastest migrating band includes non-phosphorylated Cx43 (P0 or NP) 
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and at least two slower migrating forms termed P1 and P2 (Solan & Lampe 2009) (Figure 
1.6). The P1 isoform has been shown to be due to phosphorylation of S365 (Solan et al. 
2007) while the P2 isoform has been shown to involve phosphorylation of S325/328 and 
330 (Lampe et al. 2006). In healthy hearts essentially none of the Cx43 protein migrates 
to P0 (Beardslee et al. 2000).  
 
 
 
 
Figure 1.6 Phosphorylation states of Cx43 
Taken from Solan et al. (Solan et al. 2007) showing the phosphorylation states of Cx43 in rat liver cells 
 
1.3.3 Conductance  
 
Unitary conductance through gap junctional channels varies with connexin type. In 
homotypic channels, the open conductance of Cx45 is 30–40pS (Moreno et al. 1995), of 
Cx40 is 175-210pS (Valiunas et al. 2000), and of Cx43 channels is intermediate with 
values of 60–120pS (Burt & Spray 1988, Moreno et al. 1992). Heterotypic combinations 
of gap junctional channels lead to a spectrum of biophysical properties which leads to a 
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variety of possible conductances, Cx32/Cx26 heterotypic gap junction in xenopus 
oocytes were shown to have a permeability intermediate between the two homotypic 
forms (Bukauskas et al. 1995, Cao et al. 1998). 
 
1.3.4 Selectivity 
 
Gap junctional channels show selectivity dependent on molecular charge and weight. 
Charge selectivity is dependent on the connexin isoform. Cx45 has the strongest 
selectivity for cations with a 10:1 ratio, while Cx40 favours cations at a ratio of 4:1 and 
Cx43 at only 1.2:1 (Veenstra 1996, Kanaporis et al. 2011).  
 
The pores of cardiac connexins are permeable to molecules up to 1 kDa (Moreno 2004). 
Cx43 channels are permeable to glutamate, glutathione, ADP and ATP. Cx40 is 
permeable to glutamate (Moreno 2004) and to short interfering RNA (siRNA) (Valiunas 
et al. 2005).  
 
The diversity of combinations of full channel types can lead to a variety of gating and 
selectivity properties. In vitro studies demonstrate that channels composed of different 
connexin isoforms exhibit distinctive biophysical properties. Therefore, the precise 
functional properties of gap junctions in vivo may depend on the specific connexins from 
which they are constructed and may be complex. 
 
The conductance between two neighbouring myocytes is dependent upon the number of 
gap junctional channels, the probability of an individual channel being in the open state, 
and the connexin isoforms present (Veenstra 1996).  
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1.4 Gap junction distribution in normal myocardium 
 
By electrically connecting the cytoplasm of coupled cells, gap junctions play a crucial role 
in electrical impulse propagation via intercellular transfer of ions and small molecules. 
 
Ventricular myocytes range in size from 80 to 140 m in length, and 10-30 m in width. 
They appear as cross-ribbed, elongated cells. Multiple blunt ends run at right angles to 
the long axis of the cell. The interior of a myocyte contains contractile proteins in the 
form of striated myofibrils running parallel to one another along the length of the cell. 
The myofibrils are not identical in length, giving rise to the stepped appearance to the 
cell border. Intercalated discs occur at these blunted ends and it is at these stepped ends 
that gap junctions are found in healthy myocardium (Severs 1990). When labelled with 
Cx43 antibody as shown in Figure 1.7, each cell shows multiple clusters of Cx43 gap 
juncions in the disc (Severs 2000).  
 
 
 
 
Figure 1.7 Isolated cardiomyocyte immunolabelled for Cx43 
From (Severs 2000). Clusters of gap junctions can be seen at the stepped ends at the intercalated discs 
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Although gap junctions are concentrated at the ends of the ventricular myocytes, due to 
the stepped nature of the cell membrane, they can also occur along the lateral surface of 
the membrane. Therefore, myocytes can be connected to its neighbours by both end-to-
end and side-to-side connections (Luke & Saffitz 1991) as shown in Figure 1.8.  
 
 
 
Figure 1.8 Side-to-side and end-to-end intercalated discs 
From (Luke & Saffitz 1991). Examples of intercalated discs connecting cells in side-to-side (vertical arrow) or 
end-to-end (horizontal arrow) apposition are indicated. 
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1.5 Arrhythmias 
 
Cardiac arrhythmias are a group of conditions in which the muscle contraction of the 
heart is irregular, or faster or slower than normal, preventing the heart from carrying out 
its role of pumping adequate amounts of blood around the vascular system. Abnormal 
electrical conduction in the form of slow conduction, unidirectional conduction block 
(where conduction can only propagate through an area of tissue in one direction) or 
circulating excitation/ re-entry (where there is cyclical conduction) can lead to 
arrhythmias (Kleber & Rudy 2004). Arrhythmias are likely to be multifactorial in origin 
and may arise from a combination of abnormal electrical conduction, changes in gap 
junction coupling and a change in cell and tissue architecture (Severs et al. 2008).   
1.6 Gap junction remodelling in cardiac arrhythmias 
 
Gap junctional remodelling can manifest in changes in gap junction function (for 
example a change in the open state or change in phosphorylation) or structural 
alterations (for example a change in expression levels or cellular localisation of connexin).  
Alterations to gap junction localisation and expression in arrhythmias is well documented 
in humans and in animal models (Peters et al. 1993, Peters 1995, Peters et al. 1997, van 
der Velden et al. 2000, Severs et al. 2004, Severs et al. 2006, Hesketh et al. 2009, Sheikh 
et al. 2009).  
 
Functional electrical remodelling alongside structural gap junction remodelling was first 
demonstrated in a 4-day post-myocardial infarction canine model (Peters et al. 1997).  
Dogs underwent ligation of the left anterior descending artery in order to form an 
infarct. After four days, open chested electrophyiological studies were undertaken using a 
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bipolar electrode array to investigate electrical activity over the infarct area, the epicardial 
border zone (between the infarct and surviving myocardium) and the surrounding 
myocardium. In three dogs which showed sustained monomorphic ventricular 
tachycardia (VT) a reentrant circuit of cyclical activity was mapped in the epicardial 
border zone as shown in Figure 1.9.  
 
 
 
Figure 1.9 Activation map from healing canine infarct 
From Peters (Peters et al. 1997) An example of a map of activation time showing stable re-entrant circuit during 
VT. The activation times (in ms, small numbers) are shown, as are lines of isochronal activation, at 10-ms 
intervals (larger numbers). The lines of functional block are shown as bold lines. 
 
 
The tissue under the mapped area was then excised to undergo anatomical study to 
determine the cellular localisation of Cx43 and correlate this directly with the pattern of 
electrical activation in the same tissue. Abnormally distributed Cx43 immunolabelling 
was present along the lateral surfaces of cells in the infarct epicardial border zone. These 
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changes extended through the full thickness of the surviving layer of cells and correlated 
with the site of the diastolic pathway of ventricular tachycardia circuits as shown in 
Figure 1.10. Thus gap junctional remodelling was shown alongside functional 
electrophysiological remodelling. 
 
 
 
 
Figure 1.10 Activation map and correlating connexin distribution of a healing canine 
infarct 
From (Peters et al. 1997) An example of a map of activation time showing stable re-entrant circuit during VT 
and below diagram a distribution of full-thickness disturbance of gap-junctional organisation (o indicates full-
thickness disturbance; x, partial-thickness disturbance)  showing that the two coincide. 
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Subsequently, structural gap junction remodeling has been implicated in conduction 
slowing in dilated cardiomyopathy (Akar et al. 2004), heart failure (Poelzing & 
Rosenbaum 2004), ischaemia (Lampe et al. 2006) and atrial fibrillation (van der Velden et 
al. 1998). 
 
More recently the electrophysiological consequences of a change in the function of gap 
junctional channels have come to light. Studies have suggested that dephosphorylation of 
Cx43 plays a role in electrophysiological changes.  Ischaemia has been shown to induce 
Cx43 dephosphorylation (Beardslee et al. 2000, de et al. 2008). Cx43 dephosphorylation 
has also been associated with heart failure (Ai & Pogwizd 2005, Sato et al. 2008) and 
torsade de pointes (Quan et al. 2007).  
 
1.7 Atrial Fibrillation 
 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in humans 
(Nattel 1999). It affects 1% of the general population and 8% of subjects over the age of 
80 (Aldhoon et al. 2010). AF is characterised by disorganised electrical impulses within 
the atria that result in an alteration in conduction through the atria. One of the most 
serious consequences of AF is the development of thrombi within the atrium caused by 
the sluggish nature of blood flow, which can result in stroke or pulmonary embolism 
(Hart & Halperin 1999). 
 
There are three proposed mechanisms of the spatiotemporal organisation of electrical 
activity in the atria during AF. The focal mechanism theory suggests that AF is provoked 
and possibly further driven by rapid firing of a single or multiple ectopic foci. The single 
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circuit re-entrant theory suggests the presence of a single dominant re-entry circuit. The 
multiple wavelet theory suggests the presence of multiple re-entrant circuits with 
randomly propagating wave-fronts that must find receptive tissue in order to persist 
(Aldhoon et al. 2010). 
 
Specialised cells resembling those associated with pacemaking have been identified in the 
pulmonary veins of  rats and humans (Wit & Boyden 2007). The pulmonary veins have 
been shown to be the source of ectopic beats which may initiate paroxysms of atrial 
fibrillation and can respond to treatment with radio-frequency ablation (Haissaguerre et 
al. 1998). The clinically important triggering function associated with pulmonary vein 
ectopy in humans is not well reproduced in any animal model, therefore, understanding 
of the participation and mechanism of the cardiomyocyte sleeves in the pulmonary veins 
in clinical AF is limited (Nattel 2011). 
 
 
1.7.1 Electrical remodelling in AF 
 
Electrical remodelling due to chronic high atrial rates was first described in experimental 
studies (Morillo et al. 1995, Wijffels et al. 1995). Electrical remodelling in AF tends to 
become more persistent over time (Kopecky et al. 1987) such that “AF begets AF” 
(Wijffels et al. 1995). This self perpetuating nature of AF is associated with progressive 
electrophysiological modification of the myocardium (Morillo et al. 1995). Macroscopic 
propagation velocity in atrial tissue appears unchanged in chronic AF compared with 
sinus rhythm but there is an increase in the complexity of activation (Kanagaratnam et al. 
2004). Repetitive induction of AF shortens the action potential, consequently shortening 
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the atrial effective refractory period (AERP) by up to 35% (Wijffels et al. 1995). It has 
been suggested that these changes involve alterations of intracellular Ca2+ handling. With 
each action potential, Ca2+ enters the cell through L-type Ca2+ channels. Under the 
conditions of high atrial rate, Ca2+ overload occurs. Dangerous Ca2+ overload is 
prevented by the activation of protective mechanisms, such as functional inactivation of 
L-type calcium current or down-regulation of mRNA encoding L-type calcium channels 
(Yue et al. 1997). The leads to a decrease in the calcium current and a reduction in the 
action potential duration.  
 
However, this process of electrical remodelling is reversible after restoration of sinus 
rhythm and is insufficient to explain the phenomenon of paroxysmal AF developing into 
persistent AF, due to an inconsistency in timescales. In the classical goat model, changes 
in atrial refractoriness occur within 3-5 days, but it takes 2-3 weeks for AF to become 
persistent. In a goat model of AF, maintenance of AF for 5-day periods has no 
cumulative effect on AF stability ( measured at episodes of AF over 60 seconds) (Garratt 
et al. 1999). However, maintenance of AF for 1 month results in a progressive increase in 
AF stability (Todd et al. 2004). Therefore, there may be a “second factor” influencing the 
overall remodelling process that occurs. 
 
1.7.2 Structural Remodelling in AF 
 
Prolonged rapid atrial pacing induces changes in atrial myocytes such as an increase in 
cell-size, myolysis (loss of myofibrils), perinuclear accumulation of glycogen, alterations 
in connexin expression, fragmentation of sarcoplasmic reticulum and changes in 
mitochondrial shape (Ausma et al. 1997). Atrial fibrosis has been well documented in AF 
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(Frustaci et al. 1997, Remes et al. 2008). Structural remodelling can result in electrical 
uncoupling and slow conduction, facilitating AF continuation without inducing changes 
in atrial action potential properties. In contrast to electrical remodelling, structural 
changes are less reversible and they tend to persist even after the re-establishment of 
sinus rhythm (Aldhoon et al. 2010). 
 
Gap junctional changes have been correlated with increased stability of AF (van der 
Velden et al. 2000). The role of gap junction remodelling in the development of AF 
shows an inconsistency in results. Studies of Cx43 and Cx40 expression in patients in 
chronic AF compared with sinus rhythm have shown higher levels of Cx40 
(Polontchouk et al. 2001), lower levels of Cx40 (Nao et al. 2003) and a high expression of 
Cx40 has been associated with post operative AF (Dupont et al. 2001). Immunoconfocal 
quantification of connexin label has shown no difference between AF and sinus rhythm 
(Kanagaratnam et al. 2004). Therefore further work on gap junction remodelling is 
necessary to determine its role in AF and whether this could be involved in the “second 
factor”.  
 
1.7.3 The effect of the angiotensin system in AF 
 
The enzyme renin is formed in the kidneys from prorenin. Renin acts on the substrate 
angiotensinogen to form the peptide angiotensin I. Removal of two amino acids from 
angiotensin I by angiotensin converting enzyme (ACE) leads to the formation of 
angiotensin II. Type 1 angiotensin II (AT1) receptors exist in blood vessels and the heart. 
Angiotensin receptor blockers (ARBs) are antagonists of the AT1 receptors. The 
angiotensin system is shown in Figure 1.11. 
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Figure 1.11 The angiotensin system 
Diagrammatic representation of the angiotensin system and the interaction of angiotensin receptor blockers. 
 
 
The development of atrial fibrosis is angiotensin II dependent. Increased tissue 
angiotensin II is associated with tissue fibrosis (Cardin et al. 2003). Because angiotensin 
II has a central role in the development of atrial fibrosis, inhibition of atrial ACE and 
AT1 receptors might be beneficial in AF. AF susceptibility and atrial fibrosis were 
decreased by candesartan (an AT1 receptor antagonist) or enalapril (an ACE inhibitor), 
but not by hydralazine or isosorbide mononitrate (both smooth muscle relaxants) despite 
similar hemodynamic effects (Li et al. 2001, Okazaki et al. 2006). The angiotensin system 
has also been implicated in increasing the likelihood of AF (Lendeckel et al. 2010) 
possibly by causing a self-perpetuating cycle. Irbesartan (an AT1 receptor antagonist) 
decreases the rate of AF occurrences (Madrid et al. 2004). Losartan (another AT1 
receptor antagonist) reduces new-onset AF (Wachtell et al. 2005).  
 
Infusion of angiotensin II has been shown to reduce gap junctional conductance in 
isolated rat cell pairs by action on the AT1 receptor and activation of protein kinase C 
(De & Altieri 1992). Protein kinase C activity and the presence of calcium has been 
shown to be involved in control of phosphorylation of gap junctional proteins (Figure 
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1.12) (Takeda et al. 1987). The administration of the ACE inhibitor enalapril has been 
shown to increase gap junctional conductance in cell pairs isolated from the ventricle of 
cardiomyopathic hamsters (De Mello 1996). Although the mechanism by which 
inhibition of ACE leads to increased cell coupling has not yet been identified, it has been 
suggested that it may be by reducing synthesis of angiotensin II both in the plasma and 
locally in the cardiac muscle (De Mello 2001).  
 
 
Figure 1.12 Downstream pathway of activation of the AT1 receptor  
From De Mello (De Mello 2001) 
 
 
There is little evidence as yet to suggest a connection between AT1 receptor action and 
changes to the expression and localisation of connexins and AF.  
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1.8 Scope of the thesis 
 
The aim of this thesis was to investigate the effects of modulation of the angiotensin 
system on structural correlates of electrical remodelling in atrial fibrillation and 
conversely to investigate the role of gap junction modulation on changes in electrical 
propagation, using animal and cell models. 
 
I aimed to address the following hypotheses using the goat model of AF: 
1. Structural changes, in the form of gap junction remodelling, fibrosis and 
hypertrophy, will correlate with electrical remodelling and influence the self 
perpetuation of AF.  
2. The timescale of structural remodelling will correlate with the timescale of 
increased stability of AF.  
3. The AT1 receptor antagonist, candesartan, will attenuate the remodelling seen in 
AF. 
 
Using the in vitro HL-1 cell model I aimed to investigate the following hypotheses  
1. Conduction velocities will correlate with gap junctional coupling and connexin 
expression. 
2. Areas of abnormal conduction will correlate with abnormal connexin distribution 
and expression. 
3. Administration of the gap junctional uncoupler, carbenoxolone, will lead to 
conduction slowing via a reduction in intercellular communication. 
4. Administration of the gap junctional coupler, rotigaptide, will lead to an increase 
in conduction velocity via enhancement of intercellular communication.  
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Chapter 2: General Methods 
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2.1 Introduction 
 
The general methods give an outline of the immunohistochemical and biochemical 
procedures used in this study. Further specific methodological details are given in the 
relevant individual chapters. All chemicals and reagents were supplied by Sigma-Aldrich 
and VWR unless otherwise stated. The general protocols described are those used for 
detection of Cx43 protein. Adaptations to these protocols are described as necessary in 
the relevant method sections.  
 
2.1.1 The principles of immunohistochemistry 
 
Immunohistochemistry is a technique used to investigate the localisation of a protein. It 
takes advantage of the specificity of antibody-antigen interactions to visualise proteins 
present in a sample on a slide. The tissue is prepared from frozen specimens by 
sectioning with a cryostat and is placed on a slide. Sections are fixed to prevent protein 
degradation. Methanol can be used for fixation and has the added advantage of causing 
cell membrane permeablisation which enables antibodies which bind to intracellular 
locations by passing across the membrane. Background staining can occur due to non-
specific binding of a specific antibody by hydrophobic and electrostatic forces to certain 
sites within tissue sections. This can be blocked using serum which contains a mixture of 
antibodies which will bind to most non-specific antigenic sites. A primary antibody 
against the protein under investigation can then be applied. Antibodies are formed by 
injecting an animal with a peptide sequence from the protein to be investigated. This 
stimulates an immune response and causes the animal to produce antibodies against the 
peptide. The antibody can then be purified from the serum of the immunised animal and 
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used for immunohistochemistry as it will bind specifically to the protein under 
investigation. A secondary antibody against immunoglobulins of the animal in which the 
primary antibody is produced can then be applied. This binds to the primary antibody. If 
the secondary antibody is conjugated to a fluorescent marker this can then be visualised 
under the microscope either by using an epifluorescence filter or by confocal 
microscopy. The binding of the antibodies to the sample is depicted in the illustration in 
Figure 2.1. The indirect method of using a primary and a secondary antibody has the 
benefit of allowing signal amplification through several secondary antibody reactions 
with different antigenic sites on the primary antibody.  
 
 
 
 
Figure 2.1 Illustration of the process of immunohistochemistry labelling.  
The primary antihody binds to the antigenic sites on the sample. The secondary antibody then binds to the primary 
antibody. 
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2.1.2 The principles of Western blotting 
 
Western blotting is used to quantify the level of expression of a protein. The procedure 
for Western blotting begins with protein isolation by lysis of the cells and solubilisation 
of the proteins. This is done by mechanically breaking up the cell membrane by 
sonicating and then dissolving in detergent. This is followed by a protein assay to 
determine protein concentration so that the same amount of total protein can be loaded 
for each sample for valid comparison.  
 
One dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) is then carried out. The gel is formed by cross links between bisacrylamide and 
acrylamide by a reaction catalysed by ammonium persulphate (AP) and 
tetramethylethylene diamine (TEMED). Proteins must pass through the pores formed by 
the cross-links. Those of larger molecular weight pass more slowly than lighter proteins, 
thereby leading to separation. The gel and sample buffer contain sodium dodecyl sulfate 
(SDS) to negatively charge all proteins so that separation is by molecular weight only and 
not by intrinsic protein charge. SDS also denatures secondary and non-disulfide-linked 
tertiary structures. 2-mercaptoethanol is also added to the samples to reduce disulphide 
bonds. A current is passed across the gel which causes the negatively charged proteins to 
migrate towards the positive electrode. Samples are first loaded in the wells of a stacking 
gel with a large pore size allowing all samples to reach the top of the separating gel at the 
same time. Samples then pass through a denser separating gel to separate proteins on the 
basis of size. One lane is filled with a molecular weight marker containing proteins of 
known molecular weight for comparison. 
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After separation, proteins are then transferred by electroblotting onto a polyvinylidene 
fluoride (PVDF) membrane which adsorbs protein. Blots can then be stained with a 
primary antibody in a similar fashion to immunohistochemistry, then hybridised with a 
secondary antibody to be visualised. Horse radish peroxidise (HRP) conjugated 
secondary antibodies can undergo precipitation to form a blue colour for visualisation by 
eye. For increased sensitivity, enhanced chemiluminescence (ECL) can be used. This 
causes emission of light which can be visualised by x-ray film detection. 
 
A sister gel is stained using Coomassie blue (a general protein stain). The band for actin 
and myosin can be used to standardise as a loading control since these should be 
consistent through all samples as they are structural proteins which remain stable in most 
conditions (but not all, for example during infarct). One sample is chosen to be loaded 
onto all gels. This can then be set as a standard level in arbitrary units so that all other 
samples can be compared against this to correct for any difference between gels.  
 
2.1.3 Separation of junctional and non-junctional connexin protein 
 
Gap junctional channels are formed by linking two connexons from adjacent myocytes. 
Functional gap junctional channels formed of two linked connexons can be considered 
as “docked” while single connexons (not in functional channels), in the process of 
assembly and breakdown can be considered as “undocked” as shown in Figure 2.2 
(Evans et al. 2006). 
 
  
62 
 
 
 
Figure 2.2 Assembly and breakdown of gap junctional proteins 
From Evans et al 2006. Stage 1 to 4 represent undocked connexons and stages 5 to 8 represent docked connexons 
present in intact gap junctional channels. 
 
 
The property of the strong bond between connexons in functional docked channels can 
be used to separate docked and undocked connexin protein to quantify separately by 
Western blot. Triton-X 100 (a weak detergent) has been shown to solubilise single 
connexons, but docked junctional connexons are resistant to this process (Musil & 
Goodenough 1991). When preparing lysate for Western blotting, samples can be first 
dissolved in Triton-X 100 and sonicated. After centrifugation the supernatant should 
contain undocked connexons. The pellet containing docked connexons can then be 
solubilised in a stronger detergent, such as SDS.  
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The following sections describe the methods used to apply the above general principles 
to detect the localisation and quantity of Cx43. 
 
2.2 Localisation of connexin protein by immunohistochemistry and confocal 
microscopy 
 
2.2.1 Cryosectioning of frozen tissue and slide preparation 
 
Slides were prepared from frozen samples, which had been stored at -80OC, using a 
cryostat (ThermoShandon) at -20OC. Glass slides were dipped in 0.01% poly-l-lysine 
solution for 5 minutes then left to dry overnight. Samples were cut to give a 5mm x 5mm 
surface and embedded onto the specimen holder using cryo-m-bed. The surface of the 
sample was shaved to give a smooth surface and then two sister sections of 10 m were 
cut and collected onto the slide. Slides were then stored at -20OC until use.  
 
2.2.2 General protocol for Immunolabelling (as used for Cx43) 
 
Slides were fixed in 100% methanol at -20OC for 5 minutes. Following this, all 
incubations were at room temperature. After washing in phosphate buffered saline 
(PBS), three times for 5 minutes each, sections were blocked in PBS containing 1% 
bovine serum albumin (PBS-BSA) for 30 minutes. The primary antibody was a mouse 
anti Cx43 immunoglobulin G (IgG) raised against a synthetic peptide corresponding to 
positions 252 to 270 of rat Cx43 (MAB 3067 Chemicon International) and was used at a 
1:1000 dilution in PBS-BSA and incubated for 2 hours. Slides were washed again with 
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PBS and then incubated with a secondary anti-mouse antibody labelled with Cy3 
fluorescent marker (Chemicon International) at a 1:500 dilution in PBS-BSA for 45 
minutes. Sections were then washed and mounted with Citifluor mounting media (Agar 
Scientific). Immunolabelling was initially examined by eye using an epifluorescent 
microscope and then imaged using confocal laser microscopy. Labelled slides were stored 
at +4OC in the dark to preserve fluorescence. Control experiments were carried out by 
labelling a sister slide with no primary antibody incubation step to investigate the level of 
background fluorescence.  
 
2.3 Quantification of levels of connexin protein expression by SDS-PAGE and 
Western blotting 
 
2.3.1 Preparation of tissue homogenates from frozen samples 
 
In order to break up the tissue in preparation for lysis the tissue was pulverised to a fine 
powder in liquid nitrogen using a precooled pestle and mortar. About 20mg of powder 
was transferred to an eppendorf tube and the weight was recorded. Solubilisation buffer 
containing 20% SDS (SB20 buffer) (SDS 20% w/v, 0.1mol/l Tris pH 6.8, 10mmol/l 
EDTA) (Coppen et al. 1999) was added to give a concentration of 0.1mg of frozen 
sample per l buffer. Samples were sonicated for 30 seconds to lyse the tissue and 
denature the proteins. 10 l of the sample was removed for protein estimation and 
mercaptoethanol was added to the remaining solution to give a final concentration of 
2.5% mercaptoethanol. Samples were then vortexed and stored at -80OC. 
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For samples which were to be analysed for docked and undocked Cx43, Triton 
extraction buffer (1% Triton-X 100 and a protease inhibitor cocktail in a 40mM pH8.0 
Tris/ 150mM NaCl solution) was added to the powder to give a concentration of 0.1mg 
of frozen sample per l buffer. The protease inhibitor cocktail used was Catalogue 
Number P8340 from Sigma containing a mixture of protease inhibitors with broad 
specificity for the inhibition of serine, cysteine, aspartic proteases and aminopeptidases. 
Samples were sonicated for 30 seconds to lyse the cells. The solution was centrifuged at 
20,000g for 30 minutes, resulting in a supernatant containing connexons not involved in 
gap junction channel formation (undocked) and a pellet composed of undissolved intact 
gap junctions (docked). The undocked supernatant was extracted, and the pellet was re-
suspended in the same volume SB20 as the volume of Triton extraction buffer used and 
sonicated for 30 seconds to lyse the double membranes. Docked and undocked solutions 
were combined at a 1:1 ratio to create a total sample. Equal volumes of Triton extraction 
buffer was added to the docked samples and SB20 was added to the undocked sample so 
that all samples were in the same buffer of 1:1 Triton extraction buffer/ SB20 to stop any 
differences in migration in the gel due to a difference of detergent concentrations. 
Samples were vortexed thoroughly and stored at -80OC. 
 
2.3.2 Estimation of protein content 
 
The protein content of the samples was estimated using a detergent compatible kit based 
on the Lowry method (BioRad DC Assay kit containing reagent S and solutions A and 
B). A standard curve was drawn using bovine IgG at concentrations of 0.0625, 0.125, 
0.25, 0.5 and 1mg/ml made from a stock solution diluted in SB20 diluted 20 times 
(SB20/20). Samples were diluted to 1/20 with distilled water so that all detergent 
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concentrations were the same. 125 l of A‟ was prepared for each sample from the kit 
using reagent S and solution A at a ratio of 20:1000. 25 l of sample or standard bovine 
IgG was added to A‟. This was then incubated for 30 minutes with 1ml of solution B. 
Absorbance at 750nm was then measured using a spectrophotometer and the protein 
concentration of the samples was calculated from the standard curve.  
 
2.3.3 Preparation of samples for loading onto gel 
 
Electrophoresis sample buffer (ESB20) was prepared by adding 2.5% mercaptoethanol 
and 0.05% bromophenol blue to SB20. Samples were thawed and vortexed for 30 
minutes, then diluted with ESB20 to give a final concentration of 0.5 g/ l. The sample 
buffer for docked and undocked samples was prepared by adding 10% mercaptoethanol 
and 0.5% bromophenol blue to a 1:1 mix of Triton extraction buffer (section 2.3.1) and 
SB20. This allowed the same final concentration of no less than 2.5% mercaptoethanol 
when added to the samples.   
 
2.3.4 Preparation of SDS-PAGE gels 
 
SDS-PAGE gels were prepared and run using a BioRad Mini-PROTEAN Tetra 
Electrophoresis System. Glass plates were cleaned with 70% ethanol and clipped 
together with spacers to give 1mm thickness for the gel. Polyacrylamide gels were made 
according the Laemmli discontinuous buffer system consisting of a lower separating gel 
and an upper stacking gel. The separating gel (12.5%) was made up as in table 2.1 with 
the ammonium persulfate (APS) and tetramethylethylene diamine (TEMED) being 
added last to start polymerisation.   
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 Volume (ml) 
30% Acrylamide/ 0.8% Bis 4.5 
1.5M Tris pH 8.8 2.5 
Distilled Water 3.1 
10% SDS 0.1 
10% APS 0.05 
10% TEMED 0.05 
 
Table 2.1 Solutions used to make separating gel 
 
This was poured to 2.5cm below the top of the glass plate so that the stacking gel would 
have a depth of 2.5cm (two times the depth of the wells). The gel was then topped with 
propanol to ensure an even top surface and allowed to polymerise for 1 hour. The 
propanol was then rinsed away with distilled water and the stacking gel (4.5%) was made 
up as in table 2.2 with the APS and TEMED being added last to start polymerisation. 
 Volume (ml) 
30%Acrylamide/ 0.8% Bis 1.5 
0.5M Tris pH 6.8 2.5 
Distilled Water 5.7 
10% SDS 0.1 
10% APS 0.1 
10% Temed 0.1 
 
Table 2.2 Solutions used to make stacking gel 
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A 15-well comb was then inserted into the gel and this was allowed to polymerise for 45 
minutes. Gels were then mounted in the running chamber. The upper and lower buffer 
reservoirs were filled with running buffer (0.192M Glycine/ 0.025M Tris/ 0.1% SDS).  
 
Total protein, 5.0 g, from each sample was loaded. One well was loaded with SDS-
PAGE molecular weight standards, broad range (BioRad). Empty wells were filled with 
sample buffer only. The gel was run at 60V until the dye front was through the stacker 
and subsequently run at 150V.  
 
2.3.5 Western blotting 
 
The gel was electrophoretically transferred onto a polyvinylidene fluoride membrane 
(PVDF) using the BioRad Mini Trans-Blot Electrophoretic Transfer Cell system. The 
PVDF membrane was cut to the size of the gel and sandwiched with the gel between 
filter paper and fibre pads in the cassette of the system as shown in Figure 2.3. This was 
carried out submerged in transfer buffer to keep the gel moist and any bubbles were 
removed before closing the cassette.  
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Figure 2.3 Packing of the gel and membrane into the cassette  
Source: BioRad leaflet. The gel and membrane are packed between filter paper and fibre pads before loading into 
the gel holder cassette. 
 
 
The cassette was transferred to the tank and filled with transfer buffer (running buffer 
with 10% methanol). An icepack was used to keep the tank cool at the beginning of 
transfer. Transfer was at 30V (6V/cm) overnight while stirring.  
 
2.3.6 General protocol for immunodetection of protein for quantification of 
expression (as used for Cx43) 
 
Transfer was assessed by Ponceau S staining so that the molecular weight standards and 
protein bands could be visualised. Excess Ponceau S was removed with distilled water 
then the molecular weight standards were removed and allowed to dry.  
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The membrane was blocked with non-fat dry milk (NFDM) block (Tris buffered saline 
pH7.6 (TBS)/4% NFDM/ 0.1% Tween20 [Merck]/1% blot qualified BSA) for 1hr. For 
Cx43 immunoblotting, the same primary antibody was used as for 
immunohistochemistry and was diluted 1:500 in block solution and incubated for 1hr.  
Membranes were washed thoroughly in wash buffer (TBS/ 0.1% Tween20/ 1% BSA) 
three times for 5 minutes each in wash buffer and then the membrane was incubated 
with a secondary alkaline phosphatase conjugated anti-mouse antibody (Pierce), diluted 
1:2500 in wash buffer for 1hr. Membranes were washed again with wash buffer, then 
with wash buffer containing no Tween, to prevent band smearing (as Tween reduces the 
effect of the block). The membrane was washed finally for 5 minutes in alkaline 
phosphatase buffer (0.1M Tris pH 9.5/ 0.1M NaCl/ 5mM MgCl2) and developed using 
the NBT/BCIP system (Promega Corp). Membranes are incubated with 330 g/ml nitro 
blue tetrazolium (NBT) and 165 g/ml 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) in 
alkaline phosphatase buffer. This is an alkaline phosphatase precipitating substrate which 
allows a blue colour to develop at the site of enzymatic activity. After precipitation was 
complete, the reaction was stopped by washing in distilled water. The membrane was 
then air dried.  
 
2.3.7 Commassie staining of gels 
 
For all immunoblots, a sister gel was run with 8 g total protein loaded per sample and 
stained overnight with Coomassie blue stain (50% methanol/ 10% acetic acid/ 0.1% 
Coomassie blue). Excess stain was removed with destain buffer (30% propan-2-ol/ 10% 
acetic acid) until protein bands were clearly visible. Destaining was stopped by washing in 
distilled water. Gels were then dried between two cellulose sheets (Gelwrap) to prevent 
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the gels from cracking. Connexin band intensities were corrected for total protein 
loading using the actin band on a coomassie-stained gel. 
 
2.4 Statistical analysis 
 
Statistical analyses were carried out using Prism version 4 software (GraphPad). Results 
in the text are presented as the arithmetic mean ± one standard deviation. Graphs 
represent mean with the error bar showing standard error of the mean.  Analyses of 
changes over increasing time or drug concentration for two groups were carried out 
using a t-test and those for more than two groups were carried out using analysis of 
variance (ANOVA), any post-hoc test carried out is described in the relevant sections. 
Analysis of the correlation between two variables was carried out using linear regression. 
Statistical analyses were considered significant if p was <0.05. Non-significant results are 
referred to as ns. 
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Chapter 3: Methods – Goat AF Model 
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3.1 Introduction 
 
The first goat model of AF was established by the Allessie group in 1995 (Wijffels et al. 
1995). In this model goats were anesthetised and implanted with 15 unipolar recording 
electrodes and six stimulating electrodes which were sutured epicardially to the lateral 
walls of the right and left atria. Three subcutaneous silver plates were placed for 
grounding and ECG recording. An external automatic atrial fibrillator was connected and 
delivered a 1-second burst of biphasic stimuli (20ms interval/ 4 times diastolic threshold) 
whenever sinus rhythm was detected as shown in Figure 3.1. AF was maintained for up 
to 4 weeks.  
 
 
 
 
Figure 3.1 The original burst pace protocol in the goat model of AF 
From Wijffels (Wijffels et al. 1995) showing induction of AF using the automatic fibrillation pacemaker. 
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This model determined that AF could be induced and sustained in a goat by burst pacing. 
Twenty four hours after the burst pacing was initiated AF was maintained for 20 
seconds. After two weeks AF was sustained and did not self terminate as shown in 
Figure 3.2.  
 
 
 
Figure 3.2 Maintenance of AF in the goat 
From Wijffels (Wijffels et al. 1995) showing that AF was sustained for longer than 24 hours after two weeks. 
 
 
Characterisation of the electrical remodelling in this model showed that artificial 
maintenance of induced AF resulted in a progressive increase in the duration of AF 
which became sustained (>24 hours) after 7.1±4.8 days. During the first 24 hours of AF 
the median fibrillation interval shortened from 145±18 to 108±8 ms and the inducibility 
of AF by a single premature stimulus increased from 24% to 76%. The atrial effective 
refractory period (AERP) shortened from 146±19 to 95±20 ms (-35%). At high pacing 
rates the shortening was less (-12%), indicating a reversion of the normal adaptation of 
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the AERP to heart rate. All electrophysiological changes were found to be reversible 
within 1 week of conversion to sinus rhythm (Wijffels et al. 1995).  
 
Subsequently electrical and structural remodelling in the goat model of AF has been 
further characterised, with some variations in the stimulation protocol and durations of 
the model. 
 
The monophasic action potential has been shown to be shortened in the goat model and 
this was associated with a decrease in mRNA expression of the L-type Ca2+ channel 
alpha1c gene (which contributes to the ICa,L current involved in the plateau phase of the 
action potential) and Kv1.5 potassium channel gene (IK,ur current involved in 
repolarisation) (van der Velden et al. 2000). The ultrastructural calcium distribution was 
investigated by electron microscopical analysis of calcium precipitates. This showed that 
in AF goats there was an initial increase in the number of sarcolemma-bound Ca2+ 
deposits (after 1-2 weeks). This returned to normal after 4-8 weeks and was reduced to 
below control levels after 16 weeks (Ausma et al. 2000). This is consistent with the 
theory that in AF there is early calcium overload followed by protective down regulation 
of L-type calcium channels. AF was shown to become more stable over time in this 
model. Repetitive 4-week periods of AF separated by one week of sinus rhythm showed 
a progressive reduction in the mean duration of burst pacing required to induce 
individual episodes of AF. The frequency with which AF was induced during 
extrastimulus pacing progressively increased in each successive period (Todd et al. 2004). 
It has been suggested that electrical remodelling by AF is due to the high rate of electrical 
activation itself and not mediated by changes in autonomic tone, ischemia or stretch 
(Wijffels et al. 1997). This is evidence to support the theory that “AF begets AF”. 
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Studies on the structural changes in the goat model showed changes in cellular 
substructures, such as loss of myofibrils, accumulation of glycogen, changes in 
mitochondrial shape and size, fragmentation of sarcoplasmic reticulum, and dispersion of 
nuclear chromatin (Ausma et al. 1997). Atrial dilation (measured by right atrial diameter) 
increased in the goat model of AF (Neuberger et al. 2006).  
 
Investigation of gap junctional changes in this model suggests that no significant changes 
in the overall expression of Cx40 and Cx43 occur as a result of persistent AF and there is 
no change in the distribution of Cx43 gap junctions but there is an increase in 
inhomogeneities of Cx40 pattern, with areas of low density Cx40 located between large 
areas of normal Cx40 density (van der Velden et al. 1998). The ratio between Cx40/Cx43 
protein expression (but not mRNA) was seen to be reduced with AF (van der Velden et 
al. 2000).  
 
Investigation into the effects of angiotensin II inhibition by candesartan in a goat model 
suggests a decrease in vulnerability for AF (measured by the ratio of total time in AF per 
number of bursts needed to induce sustained AF) and a decrease in fibrosis 
(Chrysostomakis et al. 2007).  
 
Longer term analysis of changes with up to 4 months sinus rhythm after 4 months AF in 
this model suggested that some changes were reversible. The AERP returned to normal 
values 2 months post-AF. Induced AF episodes still lasted for a few minutes compared 
with seconds in the control goats. Structural abnormalities were still present although to 
a lesser extent. The increased atrial myocyte diameter was back to normal at 4 months 
post-AF. Myolysis was decreased. The reduction of Cx40 that was observed during AF 
was completely reversed at 4 months post-AF (Ausma et al. 2003). 
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I used a variation of the goat model of AF to further characterise the electrical, structural 
and gap junctional changes that occur and to investigate the effect of angiotensin II on 
these changes.  
 
Live animal electrophysiological work was carried out in Manchester by Dr Mark Hall 
and Dr Senthil Kirubakaran. At sacrifice the tissue was frozen and sent to Imperial 
College London. I carried out all work commencing from this point onwards.  
3.2 Project Licence 
 
The experiment was conducted in accordance with the project licence issued by the 
United Kingdom Home Office under the Animals (Scientific Procedures) Act 1986. 
Twenty eight adult female goats were be used. This number was determined by the 
power calculation for the study.  
 
3.3 Statistical power 
 
Power analysis can be used to calculate the minimum sample size required to be 
reasonably likely to detect an effect of a given size. To determine the number of animals 
required to establish significance, if one did exist, a power calculation was carried out 
using previous similar studies. The study by Todd (Todd et al. 2004) showed that the 
mean time to prolonged (24 hour) episodes of AF was 277 hours in the first month of 
AF and 192 hours during the second month. If blockade of the AT1 receptor in this 
study were to cause attenuation there should be a smaller change, i.e. the time to 24 hour 
episodes of AF should be less than 277 hours in the second month. This study has been 
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powered to detect an effect of AT1 receptor blockade midway between the values of one 
month and two months as seen in the Todd study (234.5 hours), i.e. 50% reduction. The 
observed standard deviation for Todd was 32 hours, giving an effect size (D) of 1.33.  To 
achieve statistical significance at the 5% level, 12 (11.91) animals per group are required 
to achieve statistical significance.  
 
3.4 Summary of study protocol 
 
Live animal electrophysiological work was carried out in Manchester by Dr Mark Hall 
and Dr Senthil Kirubakaran. Twenty eight adult female goats (weight 68±9 kg) were used 
for the study. All experiments were conducted in accordance with a project license issued 
by the UK Home Office under the Animals Scientific Procedures Act 1986 after ethical 
approval.  
 
All animals were implanted with pacing systems. Figure 3.3 outlines the timelines used 
for the study protocol. Four goats were sacrificed five days after pacemaker implantation 
as sham. Evaluation of conduction velocity and tissue analysis was carried out as with 
study goats and served as control data. The remaining 24 goats entered the main part of 
the study and underwent maintenance of AF using atrial burst pacing of 50Hz for up to 
three consecutive one month periods. Twelve goats received the AT1 receptor antagonist 
candesartan orally at a dose of 0.13mg/kg daily (equivalent to a human therapeutic dose 
of 8mg per day) for one week before and for the duration of the study. The other 12 
animals received placebo. During maintenance of AF, AF cycle length, ventricular cycle 
length, AF stability, and mean duration of individual AF episodes were measured at t=0, 
4, 8, 12 and 24 hours, twice daily until 120 hours, and then every 24 hours (detailed in 
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section 3.7). After four weeks, four placebo and four candesartan-treated goats 
underwent electrophysiological analysis (detailed in section 3.9-11) prior to sacrifice when 
tissue was excised from the right atrial appendage, right atrial free wall, left atrial 
appendage, left atrial free wall, and posterior intervenous region of the left atria for 
biochemical and histological analysis (detailed in sections 3.12-14). Excised tissue was 
immediately snap frozen in liquid nitrogen and then stored at -80OC. Between each 
period of AF, goats were cardioverted and allowed to remain in sinus rhythm for one 
week, which was sufficient for electrical remodelling to completely reverse, measured by 
a return of AERP to baseline. 
 
 
Figure 3.3 Study protocol 
Timelines to show the time of pacemaker implant, maintenance of AF, sinus rhythm and sacrifice. 
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3.5 Pacemaker Implantation 
 
All 28 animals each had two pacing systems implanted. General anesthesia was induced 
and maintained with 4% isoflurane and a 2:1 mixture of nitrous oxide and oxygen. Once 
anesthetised, 5mg midazolam was administered. The goats were intubated and allowed to 
breathe spontaneously. Oxygen saturations and ECG telemetry were monitored. The 
right external jugular vein was exposed by a 6cm incision made on the right lateral aspect 
of the neck using blunt dissection and an aseptic surgical technique as shown in Figure 
3.4.  
 
 
 
 
Figure 3.4 Mobilisation of the external jugular vein 
Blunt dissection was used to expose the right external jugular vein. 
 
 
A small venotomy was made to the external jugular vein and two active-fixation bipolar 
steroid eluting leads were positioned in the right atrial appendage and one active-fixation 
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bipolar steroid eluting lead in the right ventricular apex under radiographic fluoroscopic 
guidance (Figure 3.5).  
 
 
 
Figure 3.5 Pacemaker induction through venotomy 
A] Introduction of pacemaker through venotomy. B] Radiograph showing position of pacemaker leads.  
 
 
One atrial lead was connected to a pacemaker capable of delivering short-coupled atrial 
extrastimuli (Intermedics) and the remaining atrial and ventricular leads to a pacemaker 
with a software patch enabling burst pacing (Thera® or AT501). Subcutaneous pockets 
were made on the lateral aspect of the neck of sufficient size to accommodate the two 
pacemakers. Care was taken to place the pacemakers several centimetres apart to prevent 
interactions. The wound was closed and one gram of intravenous flucloxacillin was given 
for antibiotic prophylaxis together with intramuscular buphrenorphine for analgesia. 
Following surgery goats were allowed to recover for two weeks before initiation of the 
study protocol.   
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3.6 Burst pacing protocol 
 
The software in the burst pacing pacemaker was designed to deliver two seconds of 
50Hz of atrial burst pacing at four times the diastolic threshold through the atrial lead in 
the right atrial appendage whenever two beats of sinus rhythm were detected. Burst 
pacing was inhibited when atrial fibrillation was detected as shown in Figure 3.6.  
 
 
 
 
Figure 3.6 Intracardiac atrial electrogram to show the induction of AF 
A period of sinus rhythm can be seen, then the burst pace followed by induction of AF. 
 
3.7 Measurements during maintenance of AF 
 
During maintenance of AF, AERP, AF cycle length, ventricular cycle length, AF stability 
and mean duration of individual AF episodes were measured at 0, 4, 8, 12 and 24 hours, 
twice daily until 120 hours, and then every 24 hours. AERP was measured by using a 
drive train of eight extrastimuli (S1) followed by a single extrastimus (S2) at four times the 
diastolic threshold. The initial S1-S2 coupling interval was begun at an interval shorter 
than the expected AERP and increased incrementally in 10ms steps until atrial capture 
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occurred. The AERP was defined as the longest S1-S2 that failed to capture. AF cycle 
length was measured as intervals between consecutive beats during AF. AF stability was 
measured as duration of individual episodes of induced AF and was considered persistent 
if an episode lasted over 24 hours.  
 
3.8 Measurements during the one week intervals between each AF period 
 
At the end of the 4-week period of maintenance of AF the burst pacing was switched 
off. The animals were then anesthetised as in the initial protocol.  An ECG was acquired 
and then a 360J monophasic DC shock was delivered. The rhythm was then assessed and 
if atrial fibrillation persisted a further 360J shock was delivered. In all goats three shocks 
were sufficient to cardiovert to sinus rhythm. Once sinus rhythm was achieved, the 
anaesthetic gases were removed and the goats were allowed to recover. Daily 
measurements of the AERP were taken until the AERP returned to within 5% of the 
baseline value which was considered as reversal of electrical remodelling. The burst 
pacing pacemaker was then switched on to initiate the next period of AF maintenance.  
 
3.9 Open chested electrophysiological analysis  
 
At the end of each period of AF maintenance, four placebo goats and four candesartan 
treated goats underwent epicardial mapping. The goats were anesthetised and 
cardioverted to sinus rhythm as described in section 3.8. The right atrial free wall was 
exposed via a thoracotomy. A rectangular array of 112 unipolar electrodes (Prucka Inc) 
53mm x 21mm in size with a 3.57mm interelectrode separation (Figure 3.7) was manually 
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positioned on the trabeculated right atrium and right atrial free wall such that the sulcus 
terminalis traversed the centre of the array. A silver plate (diameter 2.5cm) positioned in 
the thoracic cavity was used as a reference electrode.  
 
 
 
 
Figure 3.7 Photograph to show the Prucka mapping array 
Electrode size was 53mm x 21mm with a 3.57mm interelectrode separation. 
 
 
Electrograms were acquired using a CardiomappTM system (Prucka Inc.) at a sampling 
rate of 1kHz and bandpass filtering between 0.2Hz and 300Hz during atrial pacing and 
during AF. Atrial pacing was at a cycle length of 400ms. Recordings taken during atrial 
pacing are described in section 3.10. AF was induced by either incremental atrial pacing, 
the introduction of early atrial premature beats or by the initiation of atrial burst pacing. 
Recordings taken during AF are described in section 3.11. 
 
Off-line analysis was carried out using five consecutive beats of atrial pacing at a cycle 
length of 400ms or two seconds of AF.  
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3.10 Mapping during atrial pacing 
 
3.10.1 Measurements of conduction velocity and electrogram morphology 
 
Atrial activation maps were constructed during constant atrial pacing at 400ms intervals, 
as shown in the example in Figure 3.8. The steepest negative deflection of the atrial 
unipolar electrogram at each electrode was assigned as the activation time. Isochronal 
lines of 10ms intervals were drawn. Overall atrial conduction velocity was calculated 
using the measurement of the time taken for a wavefront to cross the mapping array and 
the distance travelled as measured perpendicular to the isochrones.  
 
 
 
Figure 3.8 Example of an atrial activation map in a control goat 
Arrow shows course of wavefront perpendicular to isochrones used to calculate distance travelled. 
 
  
86 
3.10.2 Measurements of local conduction velocities 
 
Local atrial conduction velocities were calculated by the method of triangulation 
(Kanagaratnam et al. 2004). The activation times of each electrode and the two 
neighbouring electrodes were used to calculate local conduction velocities. Five 
consecutive beats were used to find the median of the local conduction velocities for 
each electrode. To quantify the proportion of areas of slow local conduction, slow 
conduction was defined as a velocity of less than 10cm/s. Triangles were excluded if all 
three electrodes were activated simultaneously (or within 1ms) implying epicardial 
breakthrough (Kanagaratnam et al. 2004).  
 
3.10.3 Atrial electrogram morphology 
 
Unipolar right atrial electrograms from five consecutive beats of atrial pacing at a cycle 
length of 400ms at each electrode were analysed for characterisation of the electrogram 
morphology.  The atrial electrograms were characterised into three groups; single, double 
and fractionated as previously described (Konings et al. 1997) (Figure 3.9). A single 
electrogram was classed as one which exhibited a single rapid negative deflection. Double 
electrograms showed two negative deflections with the amplitude of the smaller 
deflection being no less than 25% of the larger deflection. Fractionated electrograms 
were classed as those showing three or more negative deflections within 50ms.  The 
duration of the atrial electrogram was measured from the first deviation from baseline to 
the point at which the electrogram returned to a stable baseline.  The spatial distribution 
of single, double and fractionated electrograms was drawn.  
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Figure 3.9 Representative examples of single, double and fractionated electrograms 
A single electrogram was classed as one which exhibited a single rapid negative deflection. Double electrograms 
showed two negative deflections with the amplitude of the smaller deflection being no less than 25% of the larger 
deflection. Fractionated electrograms were classed as those showing three or more negative deflections within 50ms.   
 
3.11 Mapping during atrial fibrillation 
 
3.11.1 Local conduction velocities 
 
After induction of AF by either incremental atrial pacing, the introduction of early atrial 
premature beats or by the initiation of atrial burst pacing, local conduction velocities and 
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proportion of areas with slow local conduction during AF were calculated as described 
above in section 3.10.2.  
 
3.11.2 Atrial electrogram morphology 
 
Atrial electrograms during atrial fibrillation were classified single, double and fractionated 
using the previous criteria into detailed in section 3.10.3.  
 
3.11.3 Isochronal mapping and classification of the complexity of AF 
 
Atrial activation maps were drawn as in section 3.10.1. Conduction block was defined as 
an apparent conduction velocity of less than 10cm/s combined with a clear change in 
direction of conduction distal to the line of block (Eijsbouts et al. 2003). Arrows were 
drawn to indicate the main direction of activation.  The isochronal maps were classified 
using the Koning‟s method (Konings et al. 1997) to define the complexity of activation 
(Figure 3.10). Type 1 AF was defined as a single broad wavefront propagating across the 
right atrium with only small areas of conduction block or slow conduction not disturbing 
the main course of the fibrillation wave, Type 2 AF as either one wavefront propagating 
with marked local conduction delay or two separate wavefronts present and Type 3 AF 
as three or more fibrillation waves present. The proportion of Type 1, 2 and 3 AF was 
calculated for 2 seconds of atrial fibrillation in each goat. 
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Figure 3.10 Konings classification system of isochronal maps 
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3.12 Localisation of connexin protein by immunohistochemistry and confocal 
microscopy 
 
3.12.1 Immunolabelling of Cx43 protein 
 
Slides were prepared from frozen samples as described in General Methods section 2.2.1 
The general protocol for immunolabelling for Cx43, as described in section 2.2.2, was 
used. 
 
3.12.2 Scoring system for lateralisation of Cx43 
 
One form of Cx43 remodelling may be characterised as a change in the cellular 
localisation from the normal position in the intercalated disc at the ends of myocytes to 
the lateral membrane, away from the intercalated disc (lateralisation). The degree of 
lateralisation can be used as a marker for the extent of remodelling. A semi-quantitative 
scoring system was previously devised to measure the percentage of cells showing 
lateralisation (Patel et al. 2001) (Table 3.1). Sections were viewed on an epifluorescent 
microscope by eye so that the whole area of the two sections on the slide had been 
viewed and samples were scored according to the percentage of cells with normal 
distribution of Cx43 and percentage showing lateralisation.  Where the majority of cells 
showed normally distributed Cx43 (less that 10% of cells showing lateralisation) a score 
of one was given, a score of five was given if more than 40% of cells showed 
lateralisation. Examples of scoring are shown in Figure 3.11. 
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Score % cells showing lateralisation 
1 <10 
2 10-20 
3 20-30 
4 30-40 
5 >40 
 
Table 3.1 Semi-quantitative scoring system for Cx43 lateralisation 
Sections are scored by eye to estimate the number of cells showing lateralisation of Cx43. Normal distribution with 
most of the Cx43 residing at the location intercalated disc region is scored as 1. The highest lateralisation score of 
5 is given if more than 40% of cells show lateralisation of Cx43.  
 
 
 
Figure 3.11 Image to show an example of lateralisation scoring 
Tissue fibre orientation is indicated using double ended dotted arrows. Examples of Cx43 label in the region of the 
intercalated disc are shown by vertical arrows and Cx43 along the lateral membrane are shown by horizontal 
arrows. In score 1 the majority of Cx43 immunolabel is confined to the ends of the myocytes in the location of the 
intercalated disc. In score 5 immunolabel is found along the length of the lateral membrane. Phase contrast is 
shown behind the labelling. 
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3.12.3 Assessment of the reproducibility of the scoring system 
 
All samples were assessed under blinded conditions and analysis of variance between 
assessors showed that the scoring between different assessors was similar. Repeated 
analysis of the same slides by the same assessor in different sessions was shown to have 
an intra-observer variability of 20%. Analysis of the same slides by different assessors 
was shown to have an inter-observer variability of 20%. Where scores differed it was 
never by more than one scoring point. Therefore, although this method is only semi-
quantitative and requires visual assessment by eye, an assessment of the inter-observer 
and intra-observer variability suggests that this does not introduce bias. 
 
3.12.4 Assessment of Cx43 in the region of the intercalated disc 
 
In order to assess if any lateralisation had led to a movement of Cx43 away from the 
intercalated disk, en face images were analysed to assess disc size, amount of Cx43 
expression within the disc and the number of discs with label. The intercalated disc was 
identified and the area was marked to calculate total area of the disc. The number of red 
pixels depicting Cx43 label within this area was calculated to give Cx43 expression within 
the disc. The number of discs was counted per image (230 m by 230 m). Analysis was 
carried out using Photoshop CS2 (Adobe). An example of this process is shown in 
Figure 3.12.  
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Figure 3.12 Analysis of Cx43 content in the disc 
A] Identification of an en face disc B] Marking of the area within the disc (outlined by the white dotted line) C] 
Marking of the area of Cx43 within the disc area (outlined by the white dotted lines) 
 
3.12.5 Adaptations to general protocol for immunolabelling of Cx40 
 
The general protocol for Cx43 (described in section 2.2.2) was adapted for Cx40 to 
reduce the large amount of background non-specific labelling which was seen when the 
general protocol was applied to Cx40. This antibody had not previously been used in this 
group, due to the fact that the Cx40 antibody that was generally used was raised in goat. 
Using an antibody raised in one animal on tissue of the same animal would lead to non-
specific binding and high background. Therefore a Cx40 antibody raised in rabbit was 
chosen after a literature search of antibodies compatible with goat tissue (van der Velden 
et al. 1998). The protocol was then optimised by using a range of dilutions and 
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incubation times to determine the concentrations and times which led to the most 
specific label being seen. The changes incorporated into the final protocol are described 
below. 
 
After the fixation step an incubation in 0.2% triton-X 100 for 1hr to permeablise the cell 
membrane and enhance diffusion of the antibody to the intracellular region was added. 
The blocking step of 1% PBS-BSA for 30 minutes was replaced with 2% PBS-BSA for 
30 minutes to give a stronger block than in the general protocol. The primary antibody 
was a rabbit anti Cx40 IgG raised against a 19 amino acid peptide of mouse Cx40 on the 
cytoplasmic terminal of the protein (Alpha Diagnostic International), used at a 1:200 
dilution in 2% PBS-BSA and incubated overnight. After washing, a secondary anti-rabbit 
Cy3 (Chemicon International) was used at a dilution of 1:500 in 2% PBS-BSA for 45 
minutes. For double labelling with Cx43 the general protocol for Cx43 was carried out 
simultaneously with this protocol fo Cx40 and, the secondary Cy3 for Cx40 was replaced 
with a secondary anti-rabbit FITC (Chemicon International) and used at a dilution of 
1:500 in 2% PBS-BSA for 45 minutes.  
3.13 Quantification of levels of connexin protein expression by SDS-PAGE and 
Western Blotting 
 
3.13.1 Cx43 Western blotting 
 
To detect the level of expression of Cx43, SDS-PAGE and Western blotting was carried 
out as outlined in the General Methods section 2.3. Quantification of band intensities 
was carried out using a densitometer (Biorad). One set of samples were prepared directly 
in SB20 buffer for analysis of the total Cx43 expression and another was prepared with 
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triton extraction buffer for analysis of docked and undocked protein as described in 
General Methods section 2.3.1. 
 
3.13.2 Cx40 Western blotting 
 
For Cx40 immunoblottting, the same protocol was used as for Cx43 (section 3.13.1), and 
the primary antibody used was the same anti-Cx40 as for immunohistochemsitry (section 
3.12.4) at 1:250 dilution for 1hr.  Due to the lower sensitivity of the Cx40 antibody 
compared to the Cx43 antibody, an ECL system was used for immunodetection. After 
washing, the membrane was incubated with an anti-rabbit horseradish peroxidise (HRP)-
conjugated secondary antibody (Amersham) at 1:1500 in wash buffer for 1hr. The 
membrane was developed using an ECL detection kit (Amersham). This is a 
chemiluminescence method where the HRP catalyses oxidation of luminol. This causes 
light emission which can be detected by autoradiography film. Quantification of band 
intensities was carried out using a densitometer (Biorad). 
 
3.14 Cellular and Tissue Architecture 
 
3.14.1 Hypertrophy by measurement of cell diameter 
 
10 m sections were mounted on slides as described in General Methods section 2.2.1. 
Sections were stained using a haematoxylin and eosin (H&E) protocol. Sections were 
fixed in methanol for five minutes at -20OC. The staining was then carried out at room 
temperature. Slides were placed in Harris Haematoxylin stain for 5 minutes to stain the 
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nucleus blue and then rinsed in tap water until the sections appeared blue. Stain was 
differentiated by dipping twice in acid alcohol (70% ethanol/ 1% hydrochloric acid). 
Slides were then placed in eosin for two minutes to stain cytoplasmic structures pink and 
then dipped in tap water to remove excess stain. Sections were then dehydrated in 
increasing concentrations of ethanol (70%/ 90%/ 100%/ 100%) for 30 seconds each, 
then in xylene three times for five minutes. Slides were then mounted with DPX 
mountant. Samples were imaged on a light microscope and the diameters of transversely 
orientated cells in the plane of the nucleus were measured for 30 cells per sample. 
Measurements were made using ImageJ analysis programme (National Institute of 
Health, USA) by manually marking points on the membranes of the cells where the 
measurement was to be made (Figure 3.13). 
 
 
 
 
Figure 3.13 H&E image to show measurement technique for cell size 
Measurement of cell diameter is shown for four example cells, depicted by the dotted lines 
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3.14.2 Fibrosis 
 
Elastin and collagen, which are the components of fibrotic strands, autofluoresce under 
an argon ion laser at 488nm wavelength (Fitzmaurice et al. 1989).  This property can be 
used to assess the extent of fibrosis by confocal quantification of the degree of 
autofluorescence. 10 m frozen tissue sections mounted on poly-l-lysine coated slides, as 
described in General Methods secion 2.2.1, were fixed in methanol at -20OC for five 
minutes, mounted using Citifluor mountant and imaged using a confocal microscope. 
Quantification using the ImageJ programme was used to calculate percentage 
autofluorescence in six randomly chosen fields. The original image was opened in 
ImageJ, then lipofuscin particles (lipid containing residues of lysosomal digestion) were 
removed as these also autofluoresce. Fibriotic strands can be differentiated from deposits 
of lipofuscin by shape as lipofuscin appears as dense circular areas of fluorescence 
whereas elastin and collagen appear as long fibrous strands. Finally the fibrotic strands 
were converted to a black and white image so that number of black pixels could be 
calculated. Examples of each stage of the analysis procedure are shown in Figure 3.14. 
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Figure 3.14 Method of analysis of fibrosis 
A] Original confocal image B] Removal of lipofuscin particles C] Conversion to black and white for pixel count.  
 
3.14.3 Myolysis 
 
During myolysis the space formerly occupied by sarcomeres is occupied by glycogen. 
Therefore, quantification of myolysis was performed by evaluating the percentage of 
Periodic Acid Schiff (PAS)-positive material (a stain for glucose residues) on 10 m 
frozen sections fixed immediately in formal acetic alcohol (10% formalin in acetic acid). 
Immediate fixation was necessary to prevent oxidation of the glycogen particles, 
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therefore, the slides were not stored before use. A negative control was carried out by 
digesting glycogen with diastase on sister sections prior to PAS staining to validate which 
areas of staining were specific for glycogen and not other glucose residues and to control 
for background colour. Six random images of the sections were taken using a light 
microscope (Nikon Inverted microscope Eclipse TE200). To examine the extent of 
glycogen accumulation Photoshop CS2 (Adobe) was used to place 10x10 guide squares 
to divide the image into 1% blocks and then the number of blocks containing glycogen 
were counted. Positive presence of glycogen was set as a square filled greater than 50% 
with glycogen stain as shown in Figure 3.15. 
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Figure 3.15 PAS stained section 
A] Dark pink areas represent glycogen accumulation. Arrows show examples of squares counted or rejected. B] 
Negative control treated with diastase to digest glycogen prior to PAS staining 
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Chapter 4: Methods - HL-1 Cell 
Model 
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4.1 Introduction 
 
4.1.1 In vitro models 
 
Human and animal models have their limits in the degree of manipulation that can be 
applied. For purposes of investigation of electrical conduction 3-d whole hearts or slices 
are complex. The justification of using in vitro methods firstly lies with the degree of 
manipulation which is possible, and secondly with the reduction in complexity such that 
changes can be more directly correlated with a single phenomenon.   
 
In vitro models are a simplification of more complex slices of the whole heart. The 
advantage of using an in vitro model is that it facilitates the study of complex phenomena 
by allowing breakdown into simpler components. Investigation of electrical conduction 
in 3-d models of whole hearts or slices can involve complex activation patterns which 
may be in one plane or may involve breakthrough patterns from different layers in the 
tissue. The formation of an in vitro monolayer simplifies the structure to two dimensions, 
or even one dimension if cells are grown using patterned culture techniques, which 
allows for more definitive analysis of directions of propagation. However it is necessary 
to remember that in vitro models do represent a simplification and their limitations must 
be kept in mind. Protein expression and biophysics may be different between in vivo and 
in vitro models, leading to different biochemistry and physiology. Nevertheless, it is still 
useful to take advantage of in vitro models and compare with in vivo animal models and 
humans.  
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4.1.2 The HL-1 cell line 
 
Primary cell cultures can be used for in vitro investigations. However, they do not survive 
long in culture and may introduce confounding factors due to the presence of many cell 
types in inconsistent proportions. A cell line allows for consistency of preparations of a 
single cell type which can be perpetually cultured. 
 
Early efforts at creating a cardiac muscle cell line resulted in the AT-1 cell line 
(Steinhelper et al. 1990). These cells expressed cardiac specific proteins and retained 
ultrastructural features of cardiomyocytes. However, this and other attempts at 
establishing and maintaining a cardiac cell line have failed either because of gradual loss 
of the cardiac phenotype or loss of proliferation.  
 
The HL-1 cell line is an atrial cardiac myocyte cell line which retains a differentiated 
cardiac myocyte phenotype and maintains contractile activity over indefinite passages 
(Claycomb et al. 1998). The HL-1 cell line was established from a culture of AT-1 cells 
by careful control of the culture environment. Morphological characterisation of the cell 
line showed that HL-1 cells contain a single centrally positioned nucleus surrounded by a 
circular array of contracting myofibrils. Cardiac-specific myosin and muscle-specific 
desmin intermediate filaments are present. Normal myofibril development occurs. Cells 
attach to adjacent cells via intercalated disc-like structures (Claycomb et al. 1998)(Figure 
4.1).  
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Figure 4.1 Electron micrograph of an intercalated disc in HL-1 cells 
From Claycomb (Claycomb et al. 1998) showing the presence of intercalated discs in HL-1 cells (indicated by 
arrowheads) 
 
 
Gene expression characterisation showed that cultured HL-1 cells contain a pattern of 
gene expression similar to that of adult atrial myocytes, including transcripts for -
myosin heavy chain, -cardiac actin and Cx43. Electrophysiological characterisation 
showed the presence of currents similar to sodium, potassium and L-type calcium 
currents (Claycomb et al. 1998). This indicates that the cells contain all the necessary ion 
channels, gap junctional channels and contractile apparatus needed to use this cell line in 
the investigation of conduction propagation.  
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4.2 Establishment of HL-1 subclones 
 
The HL-1 cell line showed heterogeneity, with cell populations within the line exhibiting 
different morphological and contractile properties. Five sub-clones of the HL-1 cell lines 
were obtained by Dr Emmanuel Dupont. Sub-clones were named HL1-1, HL1-2, HL1-
3, HL1-4 and HL1-6 (HL1-5 does not exist due to lack of proliferation of this clone). 
Characterisation of the subclones differs in their connexin expression patterns and ability 
to contract. Western blot analysis shows that Cx43 and Cx40 expression differ between 
subclones (Figure 4.2). Low levels of Cx45 are present, undetectable by Western blotting 
but can be demonstrated by immunofluorescence confocal microscopy. The following 
investigations use Hl-1 clone 6.  
 
 
 
 
Figure 4.2 Western blot to show expression of Cx43 and Cx40 in the HL-1 subclones 
With thanks to P. Dias. (Unpublished data) 
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4.3 Growth and care of HL-1 cell lines 
 
4.3.1 Maintenance of HL-1 cell lines 
 
Sterile procedures were carried out in a laminar flow safety cabinet. Cells were 
maintained in T25 flasks in Claycomb medium (White et al. 2004) supplemented with 
10% foetal bovine serum (FBS), 100 g/ml Penicillin/ Streptomycin, 0.1mM 
norepinephrine and 4mM L-glutamine in an incubator at 37OC/ 5% CO2. At 90-100% 
confluency cells were passaged. Culture flasks were pre-treated before cell seeding by 
coating the dishes with a solution of 0.02% gelatine and 5 g/ml fibronectin for 10 
minutes. Cells were dislodged by washing twice with PBS then incubating with 1ml 
trypsin/EDTA (0.5mg/ml trypsin, 0.2mg/ml EDTA in PBS) at 37OC for 5 to 10 
minutes until cells were loosened from the flask surface. Further trypsin digestion was 
stopped with 1ml soyabean trypsin inhibitor. The cells were then dislodged by agitation 
of the flask, washed from the flask into a centrifuge tube with PBS, and then centrifuged 
at 1000g for five minutes. The supernatant was removed and the cells were resuspended 
in 500 l Claycomb media. Cells were then diluted between 1 in 3 and 1 in 6 and reseeded 
into a new T25 flask.  
 
4.3.2 Cryostorage of HL-1 cells 
 
Frozen HL-1 cell stocks were stored in liquid nitrogen. Cells were cultured in T75 flasks. 
At confluency, cells were dislodged from the flask as for passaging using the protocol 
described in section 4.3.1. After centrifugation, the cells were resuspended in a freezing 
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medium of 95% FBS/5% dimethyl sulfoxide (DMSO) and transferred to cryovials in 
aliquots equivalent to a 1 in 3 passage of a T25 (i.e. nine aliquots per T75). Cells were 
frozen at -80OC for 24 hours before being transferred to liquid nitrogen.  
 
To thaw the cells the cryovial was thawed rapidly in a 37OC water bath, then centrifuged 
with 10ml Dulbecco's Modified Eagle Medium (DMEM) at 1000g for five minutes. The 
supernatant was removed and the cells were resuspended in supplemented Claycomb 
medium and seeded into a flask. After allowing the cells to attach for 4-6 hours the 
medium was replaced. Cells were not used for experimental studies until they had been 
passaged twice to ensure full recovery from cryostorage.  
 
4.4 Stimulation and recording of extracellular electrograms using the 
microelectrode array (MEA) system 
 
4.4.1 Overview of the MEA system 
 
The MEA system from MultiChannel Systems (Reutlingen, Germany) is a complete 
system for stimulation, recording and data acquisition.  
 
The microelectrode arrays (MEA plates) are an arrangement of 60 electrodes arranged in 
an 8 x 8 matrix (no corner electrodes exist) that allow simultaneous stimulation and 
recording (Figure 4.4). The electrodes are made from titanium nitride (TiN). They are 
planar and 30 m in diameter with a 200 m inter-electrode distance. Therefore, the 
recording area is 1.4mm x 1.4mm in size. The electrodes are set in glass and channels 
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leading to the pre-amplifier contact points are electrically isolated with silicon nitride 
(PEVCD). Standard MEA plates are made with a solid ring around the area of the 
electrodes to hold the culture medium. I devised a technique whereby 
electrophysiological recordings could be taken then immunohistochemistry could be 
carried out on the same culture by adaptation of a removable silicone cell culture 
chamber (Greiner Bio One) which can be placed onto a flat MEA plate to hold media 
(Figure 4.3). This ring can be removed after recording to allow for placing of a coverslip 
so that the MEA plate can be imaged on a confocal microscope.  
  
 
 
Figure 4.3 MEA plates 
A] A standard MEA plate with a solid ring to hold the culture medium B] An MEA plate with no ring on 
which a removable silicone cell culture chamber [C] can be placed. 
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Figure 4.4 Microelectrode Layout 
Sixty electrodes arranged in an 8 x 8 matrix (no corner electrodes exist). The electrodes are made from titanium 
nitride (TiN). They are 30 m in diameter with a 200 m inter-electrode distance.  
 
When the MEA plate is placed in the amplifier, contact pins in the lid of the amplifier 
press onto the MEA plate contact pads.  
 
Raw data from the MEA plates are amplified by a filter amplifier (Figure 4.5). This is a 
combined unit of probe interface, band pass filter and signal amplification. Typical signal 
sources are within a radius of 30 m around the electrode centre.  
 
The analogue signal acquired is digitised using an A/D board which converts analog 
signals in real time to digital data streams at a sampling rate of 50kHz (MC_Card 
hardware) and then recorded using a data acquisition programme (MC_Rack). 
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Local extracellular currents arising from the activity of the cells‟ membranal ion channels, 
result in a small potential difference that can be measured using the extracellular 
electrodes.  
 
 
Figure 4.5 Filter amplifier 
MEA plates are placed in the central green area to connect to the amplifier system. 
 
4.4.2 Preparation of cells on MEA plates 
 
The seeding technique for MEA plates was optimised to allow cells to attach as a small 
confluent monolayer centrally over the recording electrodes. Clean MEA plates were 
prepared by rinsing with 70% ethanol, washing with Virkon, rinsing with distilled water 
and then placing in a water bath at 95OC for five minutes. Plates were dessicated and 
sterilised in an oven at 100OC overnight before use. Removable rings, sterilised in 70% 
ethanol and then dried in the laminar flow cabinet were then placed on the MEA plates. 
A 5 l drop of 50ug/ml fibronectin was then placed into the centre of the plate over the 
electrodes for 10 minutes then removed and plates were left to dry. 
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During passaging of cell from a T25 flask, after resuspension in 500 l Claycomb 
medium, a 10 l drop of cells was seeded on the centre of the MEA plate. This is 
equivalent to 0.5cm2 of confluent cells. Plates were placed in the incubator and cells were 
allowed to settle for 30 minutes. The plates were then flooded with 500 l of 
supplemented Claycomb medium.  
 
4.4.3 Recording of extracellular electrograms using MC_Rack 
 
For each preparation intrinsic and paced recordings were taken at baseline and then 
under the conditions being investigated. Typically, recordings were made for 10 seconds. 
 
4.4.4 Stimulation and pacing of HL-1 cells using MC_Stimulus 
 
Stimulation was carried out using a STG stimulus generator programmed by the 
MC_Stimulus software. A biphasic pulse was generated by setting the stimulus 
programme to send 5ms of positive pulse followed by 5ms of negative pulse. This was 
followed by no pulse for the duration required to form the required cycle length for the 
desired frequency of stimulation. For example, to obtain 1Hz pulse rate there was 5ms of 
positive pulse followed by 5ms of negative pulse then 990ms of no pulse. Initial 
investigations revealed that 120% of the threshold of stimulation was consistently at 
around ± 70mA. Therefore, this current was used for the stimulation protocol unless 
there was no capture (when not every stimulus artefact was followed by a cellular 
response), in which case the current was increased to a maximum of ± 100mA (to avoid 
damage of the electrodes and the cells). 
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Conduction delay was calculated as the time between the stimulus artefact and the 
steepest part of the activation complex. This could be used to calculate the conduction 
velocity using the known distance between the stimulating electrode and the electrode of 
investigation. Therefore, the formula used was:  
 
 
 
Equation 4.1 Calculation of conduction velocity 
 
 
The amplitude of the activation complex was measured as the voltage between the 
maximum and minimum deflection. The duration of the activation complex was 
measured as the time from first deviation from baseline to the time of return to baseline. 
These measurements are shown in Figure 4.6. 
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Figure 4.6 Measurements from the MEA recordings 
An illustration of the measurements of delay, duration and amplitude of the activation complex. 
 
4.5 Immunocytochemistry on MEA plates to determine localisation of connexin 
protein 
 
After recording of electrical activity, cells on the MEA plate were fixed with methanol for 
five minutes then washed twice for five minutes in PBS and stored at 4OC overnight. All 
incubations were then carried out at room temperature. Cells were incubated with 1% 
BSA block in PBS for 1 hour (PBS-BSA). The Cx43 antibody described in the General 
Methods section 2.2.2 could not be used, as double labelling with N-cadherin was used 
to identify areas of the membrane representing intercalated disc-like areas of tight 
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adhesion. The N-cadherin antibody is also raised in mouse, therefore, there would be no 
distinction of the secondary antibodies. Cells were simultaneously incubated with the 
primary rabbit anti Cx43 and mouse anti N-cadherin antibodies for 2 hours. The anti 
Cx43 antibody was raised against a segment of the 3rd cytoplasmic domain (C-terminal 
portion) of rat Cx43 (Zymed) and used at a 1:200 dilution in BSA. The anti N-cadherin 
was raised against a recombinant protein representing a portion of the intracellular 
domain of chicken N-cadherin (Zymed) and used at a 1:500 dilution in BSA. Antibody 
dilutions were made in PBS-BSA. After washing three times for five minutes with PBS, 
cells were then incubated simultaneously with the secondary antibodies anti-rabbit Cy3 at 
1:500 dilution and anti-mouse FITC at 1:500 dilution in BSA for 45 minutes. The cells 
were then washed three times for five minutes with PBS. The removable rings on the 
MEA plates were then removed and the plates were dipped in distilled water and the 
edge was blotted on tissue paper. A coverslip was then mounted onto the plate using 
CitiFluor mountant in excess without sealing to prevent damaging the plate. MEA plates 
were then stored at 4OC and imaged within 48 hours using confocal microscopy. 
 
4.6 Pharmacological intervention of HL-1 cells 
 
4.6.1 Carbenoxolone 
 
Carbenoxolone administration was done by dissolving carbenoxolone disodium salt 
directly in supplemented Claycomb medium. This supplemented Claycomb medium + 
carbenoxolone was then added to the cell culture in the same manner as standard 
supplemented Claycomb medium. A baseline MEA recording was taken and then zero to 
400 M carbenoxolone was added for up to two hours followed by one hour washout. 
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For washout the media containing carbenoxolone was rinsed once with standard 
supplemented Claycomb medium then replaced with standard Claycomb medium. 
 
Quantification of dead cells after carbenoxolone administration was carried out using a 
trypan blue assay. Cells were grown in 12 well plates until confluency and incubated with 
800 M carbenoxolone for 4 hours. Cells were dislodged by trypsinisation as described in 
section 4.3.1. Cells were then mixed with 0.4% trypan blue solution at a 1:1 ratio and, 
after 3 minutes, 10 l were placed on a haemocytometer. The number of dead cells 
(which had incorporated blue dye) and living cells (which were not blue) were then used 
to calculate the percentage of dead cells.  
 
4.6.2 Rotigaptide 
 
A stock solution of 1000nM rotigaptide trifluoroacetate (TCA) salt was made by 
dissolving in distilled water. This was then diluted in supplemented Claycomb medium 
and added to the cell culture in the same manner. A baseline MEA recording was taken 
and then zero to 500nM rotigaptide was added for up to 24 hours.  
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4.7 Quantification of levels of connexin protein expression in HL-1 cells by SDS-
Page and Western blotting 
 
4.7.1 Separation of junctional and non-junctional connexons 
 
Cells were grown in a T25 flask until confluent. The flasks were then scraped in 3ml of 
DMEM medium twice and centrifuged at 1000g for five minutes. The supernatant was 
removed and cells were resuspended in Triton extraction buffer (as described in General 
Methods sections 2.3.1). 10μl of Triton extraction buffer was added per square 
centimetre of cells in the original flask (therefore 250 l buffer was used for a T25 flask). 
Samples were then prepared as described in General Methods section 2.3.1. 
 
4.7.2 Estimation of protein content 
 
Protein estimation was carried out as previously described in General Methods section 
2.3.2 
 
4.7.3 Preparation of samples for loading onto gel 
 
Sample buffer was prepared as described in General Methods section 2.3.3 Samples were 
thawed and vortexed for 30 minutes, then diluted in sample buffer to give a 
concentration of 5 g/ l.  
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4.7.4 Western blotting 
 
SDS Page electrophoresis and Western blotting were carried out as described in General 
Methods section 2.3.4 -5. 
 
4.7.5 Immunodetection of Cx43 for quantification of expression 
 
Transfer was assessed by Ponceau S staining so that the molecular weight standards and 
protein bands could be visualised. Excess Ponceau S was removed with distilled water 
and then the molecular weight standards were removed and allowed to dry.  
 
After establishing the general protocol for Cx43 immunoblotting (section 2.3.6), a newer 
Cx43 antibody became available which had a higher sensitivity, therefore, the protocol 
was adapted to use this antibody. The immunoblotting was carried out as in General 
Methods section 2.3.6 with the original Cx43 antibody being replaced with the primary 
antibody anti-Cx43 (Sigma C6219 rabbit primary antibody, a synthetic peptide 
corresponding to the C-terminal segment of the cytoplasmic domain (amino acids 363-
382 with N-terminally added lysine) of human/rat Cx43) which was diluted 1:2000 in 
Marvel block solution and incubated for 1hr.  The secondary antibody used was an 
alkaline phosphatase conjugated anti-rabbit antibody (Pierce), diluted 1:2000 in wash 
buffer for 1hr. 
 
Sister Coomassie gels were carried out for loading correction. 
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Chapter 5: Results - Electrical and 
Structural Analysis of the Goat AF 
model 
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5.1 Introduction 
 
Previous studies have shown that in the clinical context, atrial electrical remodelling 
refers to adaptation of the atrial effective refractory period (AERP), which occurs as a 
result of AF (Stewart et al. 2002). Wijffels and co-workers (Wijffels et al. 1995) 
demonstrated, in a chronic goat model, that the time course of electrical remodelling (48-
72hrs) is shorter than the progression to sustained AF (approximately 7 days) suggesting 
that some additional or “second factors” are operating in the self-perpetuating process. 
  
It has beed suggested that it took at least between 5 and 28 days for these “second 
factors” to develop (Kopecky et al. 1987). Van der Velden and co-workers (Morillo et al. 
1995, Wijffels et al. 1995) have suggested that a reduction in the homogeneity of gap 
junction protein Cx40 (areas of low-density Cx40 immunolabel located next to areas of 
higher Cx40 immunolabel) induced by AF occurs over a similar time period to the 
“second factor”. These changes continued to progress with increasing durations of 
maintained AF up to a maximum at 16 weeks. These authors hypothesised that 
increasing AF stability could be due to small foci of intra-atrial conduction block 
occurring alongside the observed changes in connexin distribution.  
 
The contractile and structural properties of atrial myocytes can promote the stability of 
AF and could, therefore, be involved in the “second factor”.  Cellular dedifferentiation 
includes myolysis and glycogen accumulation. Myolysis is the process of sarcoplasmic 
depletion. This may result from a prolonged reduction in contractile activity. Less 
contractile areas can become subject to passive stretch which may lead to an increase in 
cell size (Sadoshima et al. 1992). Myolysis is associated with glycogen accumulation and 
an increase in cell volume at the areas of sarcomeric loss (Ausma et al. 1997).  In humans 
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loss of contractility has been associated with delayed recovery after cardioversion (Van 
Gelder et al. 1993, Manning et al. 1994).  Heterogeneity of cellular dedifferentiation could 
lead to a dispersion of atrial refractoriness (Brundel et al. 2002) which has been found to 
enhance AF inducibility in humans (Ramanna et al. 2000).  Although atrial fibrosis has 
been documented with AF, this does not occur in all cases. A study of patients with lone 
AF suggested that 25% did not show signs of fibrosis (Frustaci et al. 1997). However, in 
goats endomysial fibrosis (within the muscle fibre) has been seen with a dissociation of 
conduction and increase in complex activation patterns in AF (Verheule et al. 2010). Due 
to the fact that recovery from these structural changes is slow (still present after 4 
months in the goat model) (Ausma et al. 2003) they could play a part in the “second 
factor”. 
 
The aim of this part of the thesis was to concurrently examine atrial electrical 
remodelling and structural changes including the expression and distribution of gap 
junctional proteins in the goat model in which the “second factor(s)” had already been 
shown to operate. The hypotheses to be addressed were: 
1. Structural changes, in the form of gap junction remodelling, fibrosis and 
hypertrophy, will correlate with electrical remodelling and influence the self 
perpetuation of AF.  
2. The timescale of structural remodelling will correlate with the timescale of 
increased stability of AF.  
 
Live animal electrophysiological work was carried out in Manchester by Dr Mark Hall 
and Dr Senthil Kirubakaran. At sacrifice the tissue was frozen and sent to Imperial 
College London. I carried out all work commencing from this point onwards.  
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5.2 Stability of atrial refractoriness  
 
To determine that electrical remodelling had been induced in this model, the atrial 
effective refractory period (AERP), AF cycle length and duration of AF was measured as 
described in Methods chapter 3.7.  
 
During the first 4-week period the AERP fell progressively in the first 120 hours when 
the refractory period had reached its lowest point. After this there was no further 
significant decrease. The AERP at a drive cycle length of 400ms fell from 165.8±10.5ms 
to 85±11.4ms (p<0.05) after 72 hours. The rate of reduction of the AERP (time to 
reduction to half way between the highest and lowest values) was not significantly 
different in each AF period as seen in Figure 5.1. 
 
 
Figure 5.1 Fall in AERP over each period of AF  
Each period of AF began with the same AERP and the rate of fall was not significantly different. AERP fell 
progressively in the first 120 hours then remained stable. n=4 at each time point. 
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The AF cycle length is a measure of the interval between fibrillatory events during AF. 
AF cycle length fell from 156.0±4.5ms to 105.0±3.8ms (p<0.05) in the first 72 hours. 
During the week of sinus rhythm between each AF period, the cycle length returned to 
baseline. There was no change in rate of fall in AF cycle length in each successive AF 
period as shown in Figure 5.2. 
 
 
 
 
Figure 5.2 Fall in AF cycle length (AFCL) over each period of AF 
AF cycle length fell in the first 72 hours. During the week of sinus rhythm between each AF period the cycle 
length returned to baseline. There was no change in rate of fall in AF cycle length in each successive AF period. 
n=4 at each time point. 
 
 
These results suggest that electrical remodelling occurs within the first few days and can 
recover (return to baseline) during the week of sinus rhythm and the effect in subsequent 
period of AF follows a similar pattern.  
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AF stability was measured by the time taken for the duration of sustained AF to last 
longer than 24 hours. In the first period of AF, stability was achieved after 252±3 hours. 
This significantly decreased to 120±8 hours in the second period and 38±8 hours in the 
third period (p<0.05) (Figure 5.3). Therefore, this supports the theory that “AF begets 
AF” (Wijffels et al. 1995).  
 
 
 
 
Figure 5.3 AF Duration in each period of AF 
In the first period of AF, stability (over 24 hours sustained AF) was achieved after 252±3 hours. This 
significantly decreased to 120±8 hours in the second period and 38±8 hours in the third period (p<0.05). n=4 
at each time point. 
 
 
Ventricular cycle length during episodes of AF remained constant (after one week 
429±39ms, at end of 1st AF period 433±25ms, at end of 2nd AF period 478±47ms, at end 
of 3rd AF period 458±58ms, p=ns).  
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5.3 Mapping during atrial pacing 
 
An electrode array system was used to characterise localised electrical remodelling and 
identify areas of heterogeneity as described in Methods chapter 3.10.1.  
 
Overall conduction velocity was measured as the time taken for the wavefront to cross 
the array. Local conduction velocities were measured between each electrode and 
considered slow if below 10cm/s. The number of areas with slow conduction was then 
expressed as a percentage of total number of interelectrode areas. There was no 
significant difference in the overall atrial conduction velocity in each successive period of 
AF during atrial pacing (control 81.7±11.7, 1st AF period 92.0±5.3, 2nd AF period 
86.3±18.0, 3rd AF period 85.0±12.0 cm/s, p=ns). However, conduction velocities 
became increasingly heterogeneous with each subsequent period of AF showing a 
progressive increase in the proportion of areas of slow atrial conduction with each cycle 
of AF (control 0.1±0.1%, 1st AF period 0.3±0.6%, 2nd AF period 6.5±3.0% and 3rd AF 
period 6.9±4.0%, p<0.05). Figure 5.4 shows examples of the activation maps seen in 
control and goats after the 3rd period of AF.  
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Figure 5.4 Examples of isochronal maps during atrial pacing  
A] A control goat showing uniform wavefront propagation, and B] A goat after the 3rd AF period showing areas 
with crowding of isochronal lines suggesting areas of slow conduction. The time taken for the wavefront to cross the 
mapping array is similar for each example (control 63ms, 3rd AF period 61ms). 
 
This suggests that although there is no macroscopic change in conduction velocity, there 
may be some underlying microscopic changes leading to heterogeneity of conduction 
within the area of the array.  
 
5.4 Atrial electrogram morphology 
 
Electrograms were classified into single, double or fractionated as described in Methods 
section 3.10.3. The percentage of single electrograms (depicting normal activation) 
reduced significantly in each successive period of AF compared to control (82.7±4.0% 1st 
AF period, 69.0±4.0% 2nd AF period, 51.7±5.0% 3rd AF period, 87.0±10.0% control, 
p<0.05). There was no change in the percentage of fractionated electrograms (depicting 
the most abnormal activation) after the first period of AF compared to control (1.3%, 
0.3% respectively) but there was an increase after the 2nd period (10.0±2.0%, p<0.05) 
(Figure 5.5).  
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Figure 5.5 Atrial electrogram morphology during atrial pacing 
A] Representative examples of right atrial unipolar electrograms during atrial pacing from goats in each group 
showing a progressive increase in disorganised activity. B] Percentage of single, double and fractionated electrograms 
in each period of AF. n=4 at each time point. 
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There was a prolongation of the atrial electrogram duration with each successive period 
of AF (30.7±4.0ms control, 46.7±10.0ms 1st AF period, 51.7±8.0ms 2nd AF period, 
52±12ms 3rd AF period, p<0.05) (Figure 5.6).  
 
 
 
 
Figure 5.6 Electrogram duration after each period of AF  
There was a prolongation of the atrial electrogram duration with each successive period of AF (30.7±4.0ms 
control, 46.7±10.0ms 1st AF period, 51.7±8.0ms 2nd AF period, 52±12ms 3rd AF period, p<0.05). n=4 at 
each time point. 
 
5.5 Mapping during atrial fibrillation 
 
There was an increase in the proportion of areas of slow atrial conduction after each 
period of AF compared to control (1st AF period 2.7±1.1%, 2nd AF period 10.2±1.2% 
and 3rd AF period 13.6±0.4%,  control 1.5±0.5%, p<0.05).  
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The proportions of single and fractionated electrograms after each period of AF showed 
a progressive decrease in percentage of single electrograms and a corresponding increase 
in fractionated electrograms with each month of AF (control 0.3%, 1st AF period 
2.3±1.2%, 2nd AF period 14.0±2.0%, 3rd AF period 23.0±3.0%, p<0.05) (Figure 5.7).  
 
 
 
 
Figure 5.7 Electrogram morphology during AF 
A] Representative right atrial unipolar electrograms during AF from goats after each period of AF showing a 
progressive increase in disorganised activity. n=4 at each time point. 
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5.6 Complexity of AF 
 
In controls atrial activation was uniform, with a single wave crossing from right to left of 
the mapping array with no areas of conduction block (goat 1 in Figure 5.8). Each 
consecutive month of AF produced activation patterns which were progressively more 
complex. After the 2nd AF period, several lines of conduction block were present, 
separating the wavefronts into multiple wavelets (goat 7 in Figure 5.8). Focal areas of 
activation within the mapping array were visible, suggesting epicardial breakthrough 
(marked by star in goats 7 and 11 in Figure 5.8). After the 3rd AF period the atrial 
activation patterns showed more complexity with large areas of conduction block, 
multiple wavelets present and more areas of focal activation, suggesting epicardial 
breakthrough (goat 11 in Figure 5.8).  
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Figure 5.8 Isochronal maps 
Examples of 10 consecutive isochronal maps of AF in a representative goat from each group. Grey lines show 
isochrones, arrows depict direction of propagation, solid lines depict block and * depict areas of focal activation. 
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Complexity of AF was classified as activation pattern Type 1, 2 and 3 according to the 
Koning‟s method (Konings et al. 1997) as described in Methods section 3.11.1. In 
controls and after the 1st period of AF the atrial activation was mostly Type 1, classified 
as a single broad wavefront, with the proportion of Type 1 activation being 77±15% and 
72±1%, respectively, p=ns. However after the 2nd and 3rd AF period the proportion of 
Type 1 activation was significantly less (25±5%, 0% respectively), this corresponded with 
a progressive increase in complexity and Type 3 atrial activation, classified as three or 
more fibrillation waves (control 0%, 2nd AF period 33±15%, 3rd AF period 83±21%, 
p<0.05) (Figure 5.9). 
 
 
 
 
Figure 5.9 Classification of complexity of activation patterns after each period of AF 
A progressive increase in the complexity of pattern of activation was seen after each subsequent period of AF. n=4 
at each time point. 
 
5.7 Connexin distribution 
 
Connexin distribution was examined to determine its possible contribution to the 
observed changes on the stability of electrical remodelling in successive periods of AF. 
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5.7.1 Lateralisation scores with increasing duration of AF 
 
For each goat, a lateralisation score was calculated as described in Methods section 
3.12.2. The mean from all five areas (right atrial appendage, right atrial free wall, 
posterior intravenous region of the left atria, left atrial free wall and left atrial appendage) 
was calculated to give a single overall score. A mean for the left and right atria was also 
calculated using the scores for the free wall and the appendage.  
 
There was no difference in the lateralisation score of Cx43 with any duration of AF when 
the mean of all areas were taken together (1st AF period 2.0±0.2, 2nd AF period 2.8±1.0, 
3rd AF period 3.3±0.7, control 2.1±0.6, p=ns). However, when the left and right atria 
were analysed separately, the right atria showed a significant change in the lateralisation 
scores of Cx43 (1st AF period 1.4±0.3, 2nd AF period 2.9±1.0, 3rd AF period 2.9±0.3, 
control 1.8±0.9, p=0.02) but there was no significant difference in lateralisation in the 
left atria (1st period AF 2.5±0.4, 2nd AF period 2.8±1.1, 3rd AF period 3.5±1.2, control 
2.5±1.2, p=ns). A post hoc Bonferroni‟s Multiple Comparison test did not indicate any 
group as significantly different, therefore there is an overall trend of change with 
increasing duration of AF, but no group alone is significantly different (Figure 5.10). A t-
test to compare control against 3 months AF only, showed a significant difference when 
the mean of all areas were taken together (p=0.04) and for the right atria (p=0.04) but 
there was no significant difference in the left atria. 
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Figure 5.10 Graphs to show lateralisation scores for Cx43 
A] There was no difference in the lateralisation score of Cx43 with any duration of AF when the mean of all 
areas were taken together or in the left atria. However, the right atria showed a significant change in the 
lateralisation scores of Cx43. A post hoc Bonferroni’s Multiple Comparison test did not indicate any group as 
significantly different, therefore there is an overall trend of change with increasing duration of AF, but no group 
alone is significantly different. n=4 at each time point. B] Example images of immunolabelling at each time point.  
A 
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Selected sections were double labelled for Cx43 and Cx40 which showed co-localisation 
of label (Figure 5.11), therefore, Cx40 lateralisation was not scored separately.  
 
 
Figure 5.11 Co-localisation of Cx43 and Cx40 
A] Cx43 distribution in red B] Cx40 distribution in green C] Overlay of Cx43 and Cx40 showing 
colocalisation D] Overlay of Cx43 and Cx40 with phase contrast showing tissue architecture 
 
 
5.7.2 Analysis of disc size 
 
In order to assess if lateralisation had led to a movement of Cx43 away from the 
intercalated disc, en face images were analysed to assess disc size, amount of Cx43 
expression within the disc and the number of discs with label as described in Goat 
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Methods section 3.12.4. There was no difference in disc size, Cx43 expression within the 
disc or number of discs (Figure 5.12).  
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Figure 5.12 Analysis of Cx43 label within the area of the intercalated disc 
There was no difference in disc size, Cx43 expression within the disc or number of discs. n=4 at each time point. 
 
5.7.3 Analysis of the heterogeneity of Cx40 label 
 
Previous studies have qualitatively characterised heterogeneity by classifying samples as 
homogeneous, homo/heterogeneous (>90% homogenous), heterogeneous or unlabelled 
(van der Velden et al. 2000). I developed a quantitative method of analysis which 
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measures percentage heterogeneity. For each sample, six randomly selected areas were 
imaged on a confocal microscope. Analysis was then carried out using Photoshop CS3 
(Adobe). A grid of 10x10 squares was placed on the image, each square representing 1% 
of the whole image. The number of squares without label was counted to give percentage 
heterogeneity. The number of adjacent squares with lack of label was used to measure 
average percentage size of areas of loss of label and number of areas of loss of label was 
counted. Diagonally connected squares were counted as separate areas. Figure 5.13 
shows an example image and which areas were calculated.  
 
  
137 
 
 
Figure 5.13 Example of an image analysed for Cx40 heterogeneity  
A] Confocal image to identify areas devoid of Cx40 label B] Phase contrast image overlays with Cx40 labelling 
In this example image 10 areas of lack of label were identified. This covered a total of 33 squares. This gave a mean of 3.3 squares in each area of lack of label. 
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5.7.4 Changes in the total area of Cx40 label 
 
The results showed that there was a significant difference in total percentage area with 
loss of Cx43 label between control and each period of AF (24.2±6.3, 24.2±9.4, 
50.0±17.9, 52.2± 18.7% respectively, p=0.02). A post-hoc bonferroni‟s test did not 
identify any specific column differences (Figure 5.14).  
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Figure 5.14 Graph to show total percentage area with loss of Cx40 label 
There was a significant different between % unlabelled area between control goats and after each period of AF. 
n=4 at each time point. 
 
5.7.5 Changes in the spread of Cx40 label 
 
The spread of Cx40 label was measured using the standard deviation of the total 
percentage area that was uncovered between the six images of each goat. This was used 
as a measure of heterogeneity of label to investigate whether all the six images showed 
the same extent of lack of label. Comparison of all periods of AF at the same time 
showed no significant difference at any time point (7.0±2.4, 7.6±3.1,  9.1±3.5, 11.2±1.8, 
p=ns). However, when a t-test was carried out to compare control with the 3rd period of 
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AF alone, the spread was greater in AF goats compared to control (p= 0.04) (Figure 
5.15). This suggests that in control goats the whole sample showed a similar spread of 
label whereas in AF goats there are some areas with more label than others. 
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Figure 5.15 Graph to show spread of total percentage area with loss of Cx40 label 
The spread was greater after the 3rd period of AF compared to control. n=4 at each time point. 
 
 
There was no difference in the average size of each unlabelled area or the number of 
unlabelled areas, nor was there any difference in the spread of the size of unlabelled 
areas.  
 
5.8 Connexin expression 
 
Western blotting was carried out using antibodies raised against Cx43 and Cx40 as 
described in Methods section 2.3. Bands were scanned and analysed using a densitometer 
to acquire a measurement of band density in arbitrary units normalised against one 
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sample, which was chosen randomly and set as 100%. For each goat, mean expression 
was calculated from all five areas (right atrial appendage, right atrial free wall, posterior 
intervenous region of the left atria, left atrial free wall and left atrial appendage) to give a 
single overall score. A mean for the left and right atria was also calculated using the 
scores for the free wall and the appendage. The total expression of connexin protein in 
the atria was calculated as Cx40 expression + Cx43 expression. The relative ratio, which 
is a parameter of the degree of intercellular coupling, was calculated as the proportion of 
Cx40 against the total connexin expression as previously described (Kanagaratnam et al. 
2004) using the following formula (Equation 5.1): 
 
 
Equation 5.1 Calculation for relative ratio of connexin expression 
 
 
5.8.1 Expression of Cx43 
 
There was no difference in the levels of expression of Cx43 (1st AF period 41.1±28.1, 2nd 
AF period 84.8±28.1, 3rd AF period 19.0±19.0, control 59.5±16.7, p=ns). An example 
blot is shown in Figure 5.16. When the means for the left and right atria were analysed 
separately, analysis of the right atria showed a significant difference (1st AF period 
27.7±13.1, 2nd AF period 84.6±29.6, 3rd AF period 32.5±32.5, control 58.6±20.8, 
p=0.02), with the post hoc Bonferroni's Multiple Comparison Test showing that the 
difference was an increase between the groups of 1st period of AF and 2nd period of AF. 
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There was no difference in the left atria (1st AF period 50.1±41.1, 2nd AF period 
84.8±35.4, 3rd AF period 17.3±17.3, control 60.1±14.0) (Figure 5.17).  
 
 
 
Figure 5.16 An example of a blot for Cx43 and its corresponding Coomassie.  
A]An example of a Western blot labelled for Cx43 and visualised using the HRP method. B] The corresponding 
Coomassie showing the actin and myosin bands used for correction of protein loading. Samples were loaded under 
blinded conditions and, therefore, are in a random order. 
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Figure 5.17 Graphs to show Cx43 expression 
There was no difference in the levels of expression of Cx43 for the mean of all areas. When the means for the left 
and right atria were analysed separately, analysis of the right atria showed a significant difference but the left did 
not. n=4 at each time point. 
 
Quantification of the top band only, to show the level of phosphorylated Cx43 only 
showed no difference between any group. Quantification of the Cx43 docked in channels 
and undocked Cx43 (not forming channels) showed no difference in the amount of 
docked Cx43 in function gap junctions.  
 
  
143 
5.8.2 Expression of Cx40 
 
There was no difference in the levels of expression of Cx40 (1st AF period 88.9±17.6, 2nd 
AF period 104.9±22.3, 3rd AF period 96.1±28.3, compared to control 118.8±44.8, p=ns). 
An example blot is shown in Figure 5.18. When the means for the left (1st AF period 
88.9±17.6, 2nd AF period 104.9±22.3, 3rd AF period 96.1±28.3, compared to control 
118.8±44.8, p=ns), and right atria (1st AF period 88.9±17.6, 2nd AF period 104.9±22.3, 
3rd AF period 96.1±28.3, compared to control 118.8±44.8, p=ns) were analysed 
separately there was still no difference in Cx40 expression with any duration of AF. 
 
 
 
 
Figure 5.18 An example of a blot for Cx40 and its corresponding Coomassie.  
A] An example of a Western blot labelled for Cx40 and visualised using the ECL method. B] The 
corresponding Coomassie showing the actin and myosin bands used for correction of protein loading. Samples were 
loaded under blinded conditions and, therefore, are in a random order. 
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5.8.3 Expression of total connexin protein 
 
The was no difference in the levels of expression of the total amount of Cx40 + Cx43 
(1st AF period 126.1±16.0, 2nd AF period 180.8±24.6, 3rd AF period 161.1±34.9, 
compared to control 178.3±35.4, p=ns). When the means for the left (1st AF period 
145.6±39.5, 2nd AF period 190.7±40.4, 3rd AF period 157.3±33.4, compared to control 
185.5±46.6, p=ns) and right atria (1st AF period 96.8±28.2, 2nd AF period 165.9±62.4, 3rd 
AF period 166.9±40.1, compared to control 167.5±21.9, p=ns) were analysed separately 
there was still no difference in total expression with any duration of AF. 
 
5.8.4 Expression of relative ratio of connexin protein 
 
There was no difference in the levels of expression of the relative ratio of Cx40/(Cx40 + 
Cx43) (1st AF period 0.70±0.19, 2nd AF period 0.53±0.11, 3rd AF period 0.60±0.08, 
compared to control 0.66±0.12, p=ns). When the means for the left (1st AF period 
0.71±0.19, 2nd AF period 0.57±0.12, 3rd AF period 0.63±0.06, compared to control 
0.66±0.12, p=ns) and right atria (1st AF period 0.70±0.18, 2nd AF period 0.48±0.12, 3rd 
AF period 0.56±0.12, compared to control 0.65±0.14, p=ns) were analysed separately 
there was still no difference in relative ratio of expression with any duration of AF. 
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5.9 Cellular and tissue architecture  
 
5.9.1 Myolysis 
 
Myolysis was measured using the protocol in Methods section 3.14.3. After the 3rd AF 
period there was a significantly higher percentage of glycogen (49.1±1.7%,) than 
compared with control (38.6±3.5%, p=0.04). Separating data into right and left atria for 
each goat; the right atria showed a significant increase in percentage glycogen between 
control (36.9±3.0%) and goats with AF (45.9%±1.1, p=0.03). No significant difference 
was seen in the left atria (Figure 5.19). 
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Figure 5.19 Figure to show percentage glycogen accumulation  
After 3 periods of AF there was a significantly higher percentage of glycogen compared with control. The right atria 
showed a significant increase in percentage of glycogen. No significant difference was seen in the left atria. n=4 at 
each time point. 
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5.9.2 Cell Size 
 
Cell diameter ( m) was used as a measure of cell size to investigate whether hypertrophy 
had occured as described in Methods section 3.14.1. For the total mean for areas, there 
was a significant change in cell size (1st AF period 19.3±2.9, 2nd AF period 20.1±2.0, 3rd 
AF period 22.4±2.5, compared to control 16.4±1.4, p=0.01). A post hoc Bonferroni‟s 
test showed that there was significant increase between sham and 3 months of AF. This 
trend was reflected in both the left (1st AF period 19.3±2.9, 2nd AF period 21.2±1.7, 3rd 
AF period 21.0±3.8, compared to control 16.0±1.3, p=0.04) and right atria (1st AF 
period 19.2±2.8, 2nd AF period 17±3.1, 3rd AF period 23.9±3.6, compared to control 
17.0±2.5, p=0.04) separately. In the left atria there was a significant change in cell size 
but a post hoc Bonferroni‟s Multiple Comparison test did not indicate any specific group 
as significantly different. Similarly, in the right atria there was a significant increase in cell 
size and post hoc analysis showed that this was between sham and the 3rd period of AF 
(Figure 5.20).  
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Figure 5.20 Graphs to show cell diameter  
There was a significant change in cell size for the mean of all areas. This trend was reflected in both the left and 
right atria. n=4 at each time point. 
 
As the change in cell diameter seemed to show incremental growth with each progressive 
cycle of AF, a test of linear regression was carried out to see if the increase had a linear 
pattern. The mean of all areas (r2=0.53, p<0.01) and the left (r2=0.38, p<0.01) and right 
atria (r2=0.43, p<0.01) separately all showed a linear correlation (Figure 5.21).  
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Figure 5.21 Graphs to show the correlation of cell diameter and duration of AF 
The mean of all areas and the left and right separately all showed a linear correlation. n=4 at each time point. 
 
5.9.3 Fibrosis 
 
Percentage fibrosis was quantified as described in Methods section 3.14.2. No significant 
difference in percentage fibrosis was seen between control (14.3±3.2%) and the 3rd 
period of AF (10.4±2.6%). Splitting the data into left (Sham 17.3±6.4%, 3rd AF period 
9.8±4.1%) and right atria (Sham 9.8±2.5%, 3rd AF period 11.2±3.1%) still showed no 
significant difference.  
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5.10 Correlation of Electrical and Structural remodelling 
 
5.10.1 Comparisons made 
 
The structural variables which were measured were: quantity of Cx43 (Westerns), 
quantity of Cx40 (Westerns), total quantity of Cx40 and Cx43 (calculated from 
Westerns), relative ratio of Cx40/(Cx40+Cx43) (calculated from Westerns), Cx43 
lateralisation score and cell diameter. 
 
The electrical variables which were measured were: conduction velocity, % single 
electrograms, % double electrograms, % fractionated electrograms, number of areas of 
slow conduction and complexity score. 
 
The multielectrode array data were split across the array into three areas so that 
measurements could be correlated with the side of the array which was over the right 
atrial free wall and that which was close to the right atrial appendage. The middle section 
was discarded. Linear regression was carried out for each comparison. 
 
5.10.2 Electrical variables correlating with Cx43 lateralisation 
 
Cx43 lateralisation correlated negatively with percentage single electrograms in the 
appendage (r2=0.4862, p=0.03). Cx43 lateralisation correlated positively with percentage 
fractionated electrograms in the appendage (r2=0.4040, p=0.05), with the number of 
areas of slow conduction in the appendage (r2=0.4988, p=0.02), and with complexity 
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score in the appendage (r2=0.4345, p=0.04), and in the free wall (r2=0.5022, p=0.02) 
(Figure 5.22). 
 
 
 
                                  
Figure 5.22 Correlation of Cx43 lateralisation with electrical variables  
Cx43 lateralisation correlated negatively with percentage single electrograms in the appendage and positively with 
percentage fractionated electrograms in the appendage, with the number of areas of slow conduction in the 
appendage, and with complexity score in the appendage and in the free wall. n=10. 
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5.10.3 Electrical variables correlating with Cx43 expression 
 
In the free wall, a negative correlation was seen with quantity of Cx43 against conduction 
velocity (r2=0.6258, p<0.01), and against percentage single electrograms (r2=0.4613, 
p=0.03). A positive correlation was seen with quantity of Cx43 against percentage 
fractionated electrograms (r2=0.4600, p=0.03), against the number of areas of slow 
conduction (r2=0.5753, p=0.01), and against complexity score (r2=0.4737, p=0.03) 
(Figure 5.23). 
 
Figure 5.23 Correlation of Cx43 expression with electrical variables  
In the free wall, a negative correlation was seen with quantity of Cx43 against conduction velocity and against 
percentage single electrograms, and a positive correlation was seen with quantity of Cx43 against percentage 
fractionated electrograms, against the number of areas of slow conduction and against complexity score. n=10. 
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5.10.4 Electrical variables correlating with Cx40 expression 
 
Correlation analysis of electrical variables against Cx40 expression and the calculations of 
total connexin expression or relative ratio of connexin expression were not significant.  
 
5.10.5 Electrical variables correlating with cell size 
 
Cell size correlated negatively with % single electrograms in the appendage (r2=0.4263, 
p=0.04). Cell size correlated positively with number of areas of slow conduction in the 
appendage (r2=0.4988, p=0.02), and in the free wall (r2=0.6348, p=0.02) (Figure 5.24). 
 
 
 
Figure 5.24 Correlation of cell size with electrical variables 
Cell size correlated negatively with % single electrograms in the appendage and positively with number of areas of 
slow conduction. In the free wall cell size correlated positively with number of areas of slow conduction. n=10 
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5.11 Discussion 
 
5.11.1 Main findings 
 
The main finding of this part of the thesis is that, in this goat model of burst pace 
induced AF, electrical remodelling is associated with progressive changes in atrial 
connexin distribution. The electrical remodelling characterised in this model includes an 
increase in the stability of atrial refractoriness, an increase in the heterogeneity of local 
conduction velocities in the absence of overall conduction changes, electrogram 
fractionation and an increase in the complexity of activation patterns. Concurrently, in 
the same model, structural remodelling includes lateralisation of the gap junctional 
protein Cx43 in the right atria, loss of label and introduction of heterogeneity of 
distribution of Cx40, myolysis and hypertrophy via an increase in cell size. Correlation of 
the electrical and structural remodelling suggests that these happen simultaneously. 
 
5.11.2 Electrical remodelling 
 
In this current work there was no change in the overall conduction velocity with AF. 
These findings are consistent with previous studies in the goat (Wijffels et al. 1995). In 
human studies, changes in atrial conduction velocity in patients with AF have been 
conflicting. P wave duration has been used as a surrogate marker of atrial conduction and 
has been found to be prolonged in patients with AF (Yamagata et al. 1999). However, a 
study of patients with paroxysmal lone AF showed no change in conduction velocity 
(Zimmermann et al. 1998). Despite no change in overall conduction velocity, this current 
work did identify areas of slow conduction.  
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Consistent with Konings‟ study (Konings et al. 1997) of patients with AF, this current 
work found an increase in complexity of activation patterns. van der Velden (van der 
Velden et al. 1998) suggested that the increase in AF stability may be due to small foci of 
intra-atrial conduction block in the absence of any change in overall conduction velocity. 
This current work also shows no change in overall conduction velocity but an increase in 
the complexity of activation and an increase in Type 3 patterns according to the Konings 
criteria of more than 3 fibrillatory wavefronts. 
 
An increase in fractionation of electrograms was also seen, as previously described in 
patients with AF (Tai et al. 2001).  
 
5.11.3 Structural remodelling 
 
Remodelling of Cx43 has been shown to be associated with arrhythmogenesis in 
previous studies. In cardiac-restricted Cx43 conditional knockout mice (Danik et al. 
2008) there were discrete areas of conduction slowing in association with ventricular 
arrhythmias. In the canine infarct there is lateralisation of Cx43 in the location of the 
epicardial border zone of the healing infarct (Peters et al. 1997).  This current work 
shows remodelling of Cx43 in the form of lateralisation with AF for the first time. 
Furthermore, the increase in Cx43 lateralisation correlates with an increase in 
electrogram fractionation and with non-uniformity of conduction measured by an 
increase in the number of areas of slow conduction. In addition, this current work has 
shown that an increase in the complexity of activation correlates with an increase in the 
redistribution score for Cx43.  
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Van der Velden (van der Velden et al. 1998) suggested that a change in the homogeneity 
of Cx40 distribution became progressively more pronounced with increasing durations of 
maintained AF up to 16 weeks. This is consistent with this current work where there is a 
loss of total Cx40 label and an increase in the heterogeneity of Cx40 spread.   
 
Interestingly, the quantity of Cx43 protein expression seemed to show an unexpected 
pattern. In the paced canine ventricle a prolongation of QRS duration and slowing of 
local intraventricular conduction was associated with a reduction of Cx43 expression 
(Patel et al. 2001). Work with Cx43 knockout mice has shown that pacing of hearts with 
reduced Cx43 expression led to the prolongation of the ventricular effective refractory 
period (Kontogeorgis et al. 2008). These studies suggest that electrical remodelling is 
associated with a decrease in Cx43 expression. This current work suggests a negative 
correlation between Cx43 quantity and both conduction velocity and number of areas of 
slow conduction. At first this seems counterintuitive. However, earlier studies were using 
ventricular models where Cx43 is the main connexin type expressed, leading to mainly 
Cx43 homomeric homotypic gap junctional channels which have been shown to be 
functional (Moreno et al. 1992). However atrial tissue expresses both Cx40 and Cx43, a 
combination which has been suggested to be non-functional (Valiunas et al. 2001). 
Therefore, an increase in Cx43 expression in the atria may be leading to an increase in 
non-functional channels. This theory would be consistent with the findings of this 
current work. Another possible explanation is that Western blotting quantifies the 
protein expression but does not give information regarding the biophysical state of the 
protein. If the Cx43 channels are in a closed state and therefore there is a reduction in 
conduction velocity, it is possible that there is a compensatory increase in Cx43 amount.  
Previous studies of human AF patients suggest that connexin remodelling predominantly 
involves changes in expression and distribution of Cx40 (Dupont et al. 2001, 
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Kanagaratnam et al. 2004). This current work confirms the role of Cx40 distribution, but 
also shows that Cx43 remodelling occurs.  
 
Myolysis and associated glycogen accumulation has been previously documented in AF 
(Ausma et al. 1997). This current work confirms that myolysis occurs in this goat model. 
It has been suggested that myolysis may lead to loss of contractility and then an increase 
in cell size (Sadoshima et al. 1992). In this current work there is an increase in cell size 
along with an increase in myolysis which is consistent with previous observations. 
 
Studies of patients with AF suggest that fibrosis plays a role in AF only in the presence 
of ventricular dysfunction or other underlying pathologies (Ohtani et al. 1995, Xu et al. 
2004, Khan & Sheppard 2006). This current work is a model of lone AF, which may 
explain the lack of fibrosis seen. 
 
5.11.4 Evidence for the “second factor” and increased stability of AF 
 
This current work demonstrates a significant correlation between the development of 
localized areas of slow atrial conduction, degeneration of atrial electrograms and gap 
junctional remodelling.  
 
The increase in expression of Cx43 in the right atria occurs between 1 and 2 months of 
AF and not between control and 1 month AF. This is consistent with the theory that 
connexin remodelling is involved in the “second factor” after the initial electrical 
remodelling has occurred.  
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This and previous studies (Ausma et al. 1997) have shown that atrial fibrosis does not 
occur in the goat model of AF. Therefore, fibrosis cannot account for the effects of the 
“second factor” in this model.  
 
It has been suggested that enhanced myolysis and perinuclear accumulation of glycogen 
are responsible for increasing AF stability (Ausma et al. 1997). This current work has 
demonstrated the presence of myolysis in this model of AF.   
 
Along with myolysis, an increase in cell size is thought to lead to a loss of contractility 
which delays recovery after cardioversion in humans (Van Gelder et al. 1993, Manning et 
al. 1994). This current work has shown that cell size increases in this model which may 
influence stability of AF and be involved in the “second factor”. 
 
In conclusion, this part of the thesis has identified elements of electrical and structural 
remodelling occurring concurrently in a goat model of AF and suggests that connexin 
remodelling, myolysis and an increase in cell size may all be involved in the second 
factor.  
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Chapter 6: Results - The Effect of 
Angiotensin Receptor Blockade in 
the Goat AF Model 
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6.1 Introduction  
 
Previous studies have speculated that angiotensin II and its intracellular signal 
transduction system are likely to mediate some of the “second factors” of AF. 
Angiotensin II is a peptide with potent vasoconstrictor properties, and acts via two 
groups of G-protein-coupled cell membrane receptors, AT1 and AT2 (Inagami et al. 
1999). It is produced by the action of angiotensin converting enzyme (ACE) and other 
enzymes on angiotensin I, itself produced by the action of renin on angiotensinogen as 
described in Section 1.7.3. All elements of the angiotensin system have been 
demonstrated in the human heart (Regitz-Zagrosek et al. 1996).  
 
Angiotensin II increases intracellular calcium (Berk et al. 1987). This increase in 
intracellular calcium leads to a reduction in action potential duration as described in 1.7.1 
 
Activation of the AT1 receptor causes activation of mitogen-activated protein kinases 
(MAP kinases), which may lead to fibrosis (Leask 2010) and hypertrophy (Ushio-Fukai et 
al. 1998) and has been associated with Cx43 expression (Matsuyama & Kawahara 2009, 
Zi et al. 2011). These structural changes may promote AF stability as characterised in 
chapter five. 
 
In rats, infusion of angiotensin II induced atrial fibrosis (Sun et al. 1997). In a canine 
model of ventricular tachypacing-induced congestive heart failure, an increase in 
interstitial fibrosis and an increased duration of burst-pace induced AF occurred 
alongside an increase in angiotensin II concentrations. Treatment with the angiotensin 
converting enzyme inhibitor enalapril reversed these effects (Li et al. 2001). Another 
study in dogs undergoing rapid atrial pacing showed that AERP shortening in dogs 
160 
infused with angiotensin II was reversed by the administration of the angiotensin 
receptor blocker candesartan (Nakashima et al. 2000).  
   
Clinical studies in patients suggest that blockade of the AT1 receptor may reduce AF 
incidence and recurrence (Pedersen et al. 1999, Madrid et al. 2002). Interpretation of 
these studies is complicated by a number of confounding factors and the underlying 
mechanisms are unknown. 
 
Atrial dilatation occurs in AF (Manning et al. 1994). This may result in mechanical stretch 
of the myocytes which can induce production of local angiotensin II (Komuro et al. 
1995). Therefore, if angiotensin II is increased due to AF and then further promotes AF, 
this may be a mechanism of self-perpetuation in AF and may contribute to the “second 
factor”.  
 
In this part of the thesis I aimed to use the AT1 receptor antagonist, candesartan, as to 
tool to investigate if angiotensin receptor blockade attenuates the electrical and structural 
remodelling that occurs in the goat model of AF. The hypothesis to be addressed was 
that the AT1 receptor antagonist, candesartan, will attenuate the remodelling seen in AF. 
 
Live animal electrophysiological work was carried out in Manchester by Dr Mark Hall 
and Dr Senthil Kirubakaran. At sacrifice the tissue was frozen and sent to Imperial 
College London. I carried out all work commencing from this point onwards.  
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6.2 Assessment of biological activity of candesartan 
 
Candesartan reduces blood pressure via antagonism of angiotensin II-induced 
vasoconstriction. To check that a therapeutic level of candesartan had been reached in 
this goat model, blood pressure was measured firstly after infusion of angiotensin II then 
after administration of candesartan. 
 
 Angiotensin II was infused in goats at a rate of 40ng/kg/min. This increased systolic 
blood pressure by 34.0±1.9 mmHg (p=0.02), diastolic blood pressure by 
29.0±1.3 mmHg (p<0.01) and mean blood pressure by 30.3±2.7 mmHg (p<0.01) 
compared to baseline.  
 
The effect of angiotensin II infusion was attenuated by administration of oral 
candesartan (Figure 6.1). A dose of 0.5 mg/kg/day reduced the angiotensin II-mediated 
increase in systolic blood pressure from 34.1±1.9 mmHg to 8.2±3.2 mmHg (p<0.01). 
Diastolic blood pressure was reduced from 28.6±10.3 mmHg to 11.9±8.1 mmHg 
(p<0.01) and mean blood pressure from 28.1±7.7 to 10.9±7.3 mmHg (p<0.01). This 
dose attenuated the response to infused angiotensin II by 76%, therefore, this dose was 
chosen to be used in subsequent experiments. The dose of 0.5 mg/kg/day for a 60 kg 
goat (30 mg/day) is comparable to the maximum licensed human clinical dose of 
32 mg/day.  
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Figure 6.1 Attenuation of angiotensin II blockade by oral candesartan administration 
The effect of angiotensin II infusion was attenuated in goats by administration of oral candesartan. Systolic, 
diastolic and mean blood pressure was reduced compared to control. n=4 at each time point. 
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6.3 Effects of candesartan on electrical remodelling 
 
6.3.1 Effects of candesartan on rate of fall of AERP 
 
To determine electrical remodelling in the model the atrial effective refractory period 
(AERP), AF cycle length and duration of AF was measured as described in Methods 
chapter 3.7. Candesartan had no effect on the baseline atrial refractory period (Figure 
6.2). Baseline AERP at a drive cycle length of 400 ms was 170.0±9.3 ms before 
administration of candesartan and 169.2 ± 10.6 ms after one week of oral candesartan. 
There was a progressive fall in atrial refractory period in both placebo and candesartan 
groups. Candesartan had no effect on the rate or degree of fall in AERP with any 
duration of AF.  
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Figure 6.2 Comparison of AERP in placebo and candesartan treated goats 
Candesartan had no effect on the baseline atrial refractory period. n=4 at each time point. 
  
165 
6.3.2 The effect of candesartan on AF inducibility and stability of atrial 
refractoriness 
 
There was no difference in AF inducibility between placebo and candesartan groups 
(Figure 6.3). After 48 hours, 10 of 12 goats in the placebo group and 11 of 12 goats in 
the candesartan group had inducible AF. 
 
Placebo-treated goats showed a significant cumulative increase in AF stability with 
successive period of AF. There was no attenuation in the time taken for AF to become 
stable (lasing over 24 hours) in candesartan treated goats which showed an almost 
identical pattern of increasing AF stability. 
 
 
 
 
Figure 6.3 Changes in mean duration of burst pacing required to induce AF episodes 
There was no difference in AF inducibility between placebo and candesartan groups. After 48 hours, 10 of 12 
goats in the placebo group and 11 of 12 goats in the candesartan group had inducible AF. n=4 at each time 
point. 
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AF cycle length (AFCL) shortened progressively with increasing duration of AF. There 
was no difference in the rate or degree of fall between placebo and candesartan groups 
(Table 6.1). 
 
 
Table 6.1 AF cycle length in placebo and candesartan treated goats  
AF cycle length (AFCL) shortened progressively with increasing duration of AF in both candesartan and placebo 
groups. For each time point there was no significant difference between the candesartan group and the corresponding 
control group. However, there was a significant fall between 24hours and 28 days for each period of AF. n=4 at 
each time point. 
 
Ventricular cycle length during AF remained constant throughout the 28-day period. 
There were no significant differences between placebo and candesartan groups. 
 
6.4 Effects of candesartan on circulating angiotensin II levels 
 
There were no significant changes in circulating angiotensin II levels in control goats. 
Each period of AF led to an increase in circulating angiotensin II levels in placebo goats 
(1st AF period 90.5 ± 21.1% p < 0.0001, 2nd AF period 105.4 ± 26.8%  p < 0.0001, 3rd 
AF period 124.0 ± 23.7% p = 0.02). 
 
Candesartan treated goats also showed an increase in circulating angiotensin II levels 
during each successive AF period compared to control (1st AF period 95.6 ± 24.2% 
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p<0.0001, 2nd AF period 79.3 ± 49.9% p <0.01, 3rd AF period 103.0 ± 27.7% p = 0.02). 
There were no significant differences in circulating angiotensin II levels between 
placebo- and candesartan-treated animals (Figure 6.4). 
 
 
 
 
Figure 6.4 Effects of candesartan on circulating angiotensin II levels in each period of AF 
There were no significant differences in circulating angiotensin II levels between placebo- and candesartan-treated 
animals. n=4 at each time point. 
 
  
168 
6.5 Effect of candesartan during atrial pacing 
 
6.5.1 Effect of candesartan on conduction velocities 
 
An electrode array system was used to characterise localised electrical remodelling and 
identify areas of heterogeneity as described in Methods chapter 3.10.1. Candesartan had 
no effect on overall conduction velocities with any duration of AF (Figure 6.5).  
 
 
Figure 6.5 The effect of candesartan on the overall right atrial conduction velocity  
Candesartan had no effect on overall conduction velocities after any duration of AF. n=4 at each time point. 
 
 
In addition there was no difference in the development of areas of slow conduction, 
defined as the percentage of local areas where conduction was slower than 10cm/s 
(Figure 6.6).  
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Figure 6.6 The effect of candesartan on the development of areas of slow atrial 
conduction 
There was no difference in the development of areas of slow conduction. n=4 at each time point. 
 
6.5.2 Effect of candesartan on atrial electrogram morphology 
 
Electrograms were classified into single, double or fractionated as described in Methods 
section 3.10.3. The increase in fractionation of electrograms seen in placebo goat was not 
attenuated by candesartan (Figure 6.7).  
 
 
Figure 6.7 The effect of candesartan on electrogram morphology during pacing 
The increase in fractionation of electrograms seen in placebo goat was not attenuated by candesartan. n=4 at each 
time point. 
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The prolongation of atrial electrogram duration that was seen in placebo goats was not 
attenuated by candesartan administration (Figure 6.8).  
 
 
 
Figure 6.8 The effect of candesartan on the atrial electrogram duration during pacing 
The prolongation of atrial electrogram duration that was seen in placebo goats was not attenuated by candesartan 
administration. n=4 at each time point. 
 
6.6 Effect of candesartan during atrial fibrillation 
 
6.6.1 Effect of candesartan on conduction velocities 
 
The increase in the number of areas of slow conduction seen in placebo goats was not 
attenuated by candesartan administration (Figure 6.9).  
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Figure 6.9 The effect candesartan on the development of local atrial conduction slowing  
The increase in the number of areas of slow conduction seen in placebo goats was not attenuated by candesartan 
administration. n=4 at each time point. 
 
6.6.2 Effect of candesartan on atrial electrogram morphology  
 
In the candesartan treated animals the proportion of single, double and fractionated atrial 
unipolar electrograms followed a similar pattern to the placebo goats, with each 
subsequent AF period demonstrating a progressive decrease in single electrograms and 
an increase in fractionated electrograms (Figure 6.10). 
 
 
Figure 6.10 The effect candesartan on the atrial electrogram morphology during atrial 
fibrillation  
In the candesartan treated goat the proportion of single, double and fractionated atrial unipolar electrograms 
followed a similar pattern to the placebo goats. n=4 at each time point. 
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6.6.3 Effect of candesartan on complexity of atrial activation 
 
Complexity of AF was classified as activation pattern Type 1, 2 and 3 according to the 
Konings‟ method (Konings et al. 1997) as described in Methods section 3.11.1. Placebo 
goats showed a progressive increase in the complexity of atrial activation during AF. 
There was no difference in the complexity of atrial activation during AF between the 
placebo goats and the candesartan group (Figure 6.11). 
 
 
 
 
Figure 6.11 The effect of Angiotensin receptor blockade on the type of atrial activation 
during AF  
There was no difference in the complexity of atrial activation during AF between the placebo goats and the 
candesartan group. n=4 at each time point. 
 
6.7 Connexin distribution 
 
Lateralisation of Cx43 is seen in the right atria in placebo goats. There was significant 
attenuation in overall lateralisation scores after the 3rd period of AF with candesartan 
(1.6±0.9, p=0.04) compared with placebo (3.3±0.7). When split into the right and left 
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atria, there were no significant differences in the left atria, however, in the right atria 
there was a significant change in redistribution scores at 3 months (placebo 2.9±0.31, 
candesartan 1.5±0.86, p=0.01) (Figure 6.12).  
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Figure 6.12 Changes in Cx43 redistribution with Candesartan 
A] There was significant attenuation in redistribution scores after the 3rd period of AF with candesartan compared 
to the 3rd period of AF with placebo. When split into the right and left atria, there was a difference in the right 
atria but not in the left. B] Example images of immunlabelling of Cx43 in placebo with lateralisation (marked 
with arrow) and after treatment with candesartan with normal Cx43 distribution. n=4 at each time point. 
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6.8 Connexin Expression 
 
For each goat, mean expression was calculated from all areas of the right and left atria to 
give a single overall score. A mean for the left and right atria was also calculated using the 
scores for the free wall and the appendage. The total expression of connexin protein in 
the atria was calculated as Cx40 expression + Cx43 expression. The relative ratio was 
calculated as the amount of Cx40 as a proportion of the total connexin expression as 
previously described (Kanagaratnam et al. 2004). These calculations are described in 
Chapter 5.8. 
 
Analysis of Cx43 protein expression showed an increase between the 1st and 2nd periods 
of AF in the right atrium. Taking into consideration all time points for placebo and 
candesartan treated goats, an ANOVA still showed a significant difference between 
placebo goats after the 1st and 2nd periods of AF (p=0.034) but did not show any 
difference with candesartan treated goats (Figure 6.13).   
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Figure 6.13 Cx43 expression in placebo and candesartan treated goats in the right atrium  
There was an increase of Cx43 protein expression between the 1st and 2nd periods of AF in the right atrium in 
placebo goats. Taking into consideration all time points for placebo and candesartan treated goats, an ANOVA 
still showed a significant difference between placebo goats after the 1st and 2nd periods of AF but did not show any 
difference with candesartan treated goats. n=4 at each time point. 
 
 
Expression of Cx40 protein, the total connexin expression (Cx40+Cx43) and relative 
ratio of connexins Cx40/(Cx40 + Cx43) did not change in placebo goats. There was no 
change seen in candesartan treated goats.  
6.9 Cell size 
 
Cell diameter ( m) was used as a measure of cell size as described in Methods section 
3.14.1. An increase in cell diameter was seen with each successive period of AF in 
placebo treated goats. A comparison of all placebo and candesartan goats still showed an 
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increase in cell diameter (p=0.01 over all groups), but a post hoc Bonferroni‟s showed no 
difference between placebo and candesartan groups (Figure 6.14).  
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Figure 6.14 Cell size in placebo and candesartan treated groups 
An increase in cell diameter was seen with each successive period of AF in placebo treated goats. Candesartan 
treated goats showed no attenuation of this increase. n=4 at each time point. 
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6.10 Discussion 
 
 6.10.1 Main findings 
 
Chapter five describes the development of AF-induced local atrial conduction and 
electrogram abnormalities alongside structural and connexin remodelling which may be 
indicative of the operation of the „second factor‟. This part of the thesis was an 
investigation of the effect of angiotensin receptor blockade on these remodelling 
processes. This investigation showed that there was no effect on electrical and structural 
remodelling, apart from attenuation of the remodelling of Cx43, in the goat model of AF 
when the AT1 receptor antagonist, candesartan, was administered.  
 
Despite showing that candesartan is absorbed orally in the goat and has biological activity 
in reducing blood pressure via action on the vascular AT1 receptor, candesartan had no 
effect on the shortening of the AERP or AF stability. There was no effect on either 
overall conduction velocity or the development of localised atrial conduction slowing 
during atrial pacing and AF and, therefore, no effect on the development of abnormal 
fractionated atrial electrograms. The complexity of atrial activation was unchanged. 
Candesartan administration had no effect on cell size. However, the increase in the 
lateralisation score and expression of Cx43 seen in placebo goats with AF was attenuated 
in goats treated with candesartan. 
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6.10.2 Effect of angiotensin receptor blockade on electrical remodelling 
 
This current work showed that candesartan administration had no effect on the 
remodelling of AERP, conduction velocities or electrogram morphology that was seen in 
placebo goats. In a short-term (three hours) model of rapid atrial pacing in a canine 
model, administration of candesartan or the angiotensin converting enzyme (ACE) 
inhibitor captopril led to attenuation of the shortening of the AERP (Nakashima et al. 
2000). However, longer-term administration of the ACE inhibitor enalapril in a canine 
atrial tachypacing model suggests that the effect is not sustained past one week 
(Shinagawa et al. 2002).  In another study of rapid atrial pacing in a canine model it was 
suggested that the effect of candesartan in preventing promotion of AF may be via its 
effects on structural remodelling and interstitial fibrosis. This study showed that 
candesartan administration led to a shortening of AF duration along with histological 
studies showing a reduction in fibrosis. Therefore, the lack of attenuation of electrical 
remodelling in this current work may be due to the lack of fibrosis with AF.  
 
In a canine model of ventricular tachypacing, leading to congestive heart failure, followed 
by burst pace induced AF it was shown that there was an increase in atrial conduction 
heterogeneity and fibrosis (Li et al. 1999). Later the same group showed that these 
changes were attenuated by the ACE inhibitor enalapril (Li et al. 2001). They concluded 
that congestive heart failure increases angiotensin II, leading to structural remodelling 
which may be a substrate for atrial arrhythmogenesis and that ACE inhibition may 
interfere with the signal transduction in these processes. Therefore, it may be that the 
mechanism of attenuating atrial arrhythmogensis by blockade of the action of 
angiotensin II may require the presence of underlying ventricular dysfunction and its 
consequential increase in angiotensin II. Clinical studies show a similar trend, that the 
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greatest benefit of angiotensin system blockade is in those patients with structural heart 
disease (Pedersen et al. 1999). In concordance with this, a subsequent study of patients in 
whom significant structural heart disease or hypertension had been excluded showed that 
the AT1 receptor antagonist, irbesartan, was ineffective at reducing AF occurrence 
(Madrid et al. 2004). In this current work there was no change in ventricular cycle length 
suggesting that this is a model of lone AF, which may explain why there was no reversal 
of electrical remodelling in the absence of ventricular dysfunction.  
 
6.10.3 Effect of angiotensin receptor blockade on structural remodelling 
 
In this current work placebo treated goats showed gap junctional remodelling via an 
increase in the lateralisation score and expression of Cx43. On administration of 
candesartan this remodelling was attenuated.  
 
In previous studies angiotensin II has been associated with Cx43 remodelling. In the left 
ventricle of spontaneously hypertensive rats Cx43 expression was upregulated and 
lateralisation was seen. This was attenuated by the administration of the AT1 receptor 
antagonist, losartan (Zhao et al. 2008). In left atrial samples of patients with AF, 
increased angiotensin II concentrations were associated with increased fibrosis and up-
regulation of the intercalated disc protein N-cadherin and Cx43 expression (Adam et al. 
2010). In this current work no fibrosis was seen, therefore, the mechanism of attenuation 
cannot be via involvement of fibrosis. However, Cx43 remodelling has been observed in 
cell models where fibrosis cannot occur, suggesting that Cx43 remodelling does not 
always require fibrosis to be present. Upregulation of Cx43 in neonatal rat ventricular 
myocytes which underwent rapid electrical stimulation was accompanied by an increase 
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in angiotensin II secretion and was reversed by the AT1 receptor antagonist, losartan 
(Inoue et al. 2004). Another study of cyclic mechanical stretch–induced polarisation of 
Cx43 in neonatal rat cardiomyocytes (mimicking the formation of gap junctions in the 
intercalated disc) showed that this polarisation was reduced by the addition of 
angiotensin II (Salameh et al. 2010). These two studies were carried out after 24 hours 
and 60 minutes of induction, respectively, suggesting that the mechanism of angiotensin 
II remodelling of Cx43 is a short-term process not via a pathway involving fibrosis. It is 
possible that the attenuation of Cx43 remodelling seen in this current work is by a similar 
mechanism to that of these previous studies. Although, the actual cellular process via 
which the mechanism occurs still remains unknown, it has previously been suggested that 
angiotensin II leads to dysregulation of the normal localisation of Cx43 via activation of 
ERK1/2 and p38 pathways (Salameh et al. 2010). Therefore, it is possible that 
candesartan administration in this model is preventing activation of this pathway. 
 
This current work showed that the increase in cell diameter seen in placebo goats was 
not reversed by the administration of candesartan. This suggests that the mechanism is 
not via an involvement the angiotensin system. Myolysis and contractile dysfunction in 
AF is well characterised as described in Chapter 5.1. The Allessie group (Wijffels et al. 
1995) described that, in the goat model of AF, contractile remodelling (reduction of the 
atrial work index) and electrical remodelling (shortening of AERP) followed exactly the 
same time course when measured during AF for five days and then during sinus rhythm 
for five days following cardioversion. As these two processes occurred over the same 
timescales, the authors suggested that contractile remodelling and electrical remodelling 
occur via the same mechanism. Since the main cellular mechanism responsible for 
electrical remodelling is the reduction of the L-type Ca2+ inward current (Yue et al. 1997), 
it is possible that atrial contractile dysfunction during AF is also due the reduction of the 
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L-type Ca2+ inward current (Schotten et al. 2003, Schotten et al. 2003) rather than due to 
the angiotensin system.  
 
In conclusion, this part of the thesis has shown that, in this goat model of AF, 
angiotensin receptor blockade by the administration of candesartan has no effect on the 
shortening of the AERP or AF stability. There was no effect on either overall conduction 
velocity or on the development of localised atrial conduction slowing during atrial pacing 
and AF or on the development of abnormal fractionated atrial electrograms. The 
complexity of atrial activation was unchanged. Candesartan administration had no effect 
on cell size. However, the increase in the lateralisation score of Cx43 and change in Cx43 
expression seen in placebo goats with AF was attenuated in goats treated with 
candesartan.   
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Chapter 7: Results - The effects of 
fast pacing on gap junctional 
distribution in HL-1 cardiomyocytes 
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7.1 Introduction 
 
As described in chapter 4.1.2, the HL-1 atrial cardiac myocyte cell line retains a 
differentiated cardiac myocyte phenotype and maintains contractile activity over 
indefinite passages and is currently the only immortal cardiac cell line (Claycomb et al. 
1998). Gene expression characterisation showed that cultured HL-1 cells contain a 
pattern of gene expression similar to that of adult atrial myocytes indicating that the cells 
contain all the necessary ion channels, gap junctional channels and contractile apparatus 
needed to use this cell line in the investigation of conduction propagation (Claycomb et 
al. 1998).  
 
Conduction block is the phenomenon of lack of propagation of conduction. Conduction 
block can be anatomical, where there is a non-conductive obstruction (for example an 
area of fibrosis) in the path of conduction propagation (Allessie et al. 1989). Functional 
block is where the electrophysiological properties of the myocytes is impaired leading to 
lack of conduction. Re-entrant circuits are a continuous cycling of action potential 
propagation around an area of block. They can arise if the time taken for the impulse to 
propagate around the area of block is longer than the refractory period (Allessie et al. 
1977, Bian & Tung 2006). Therefore, by the time the impulse returns to the cells 
proximal to the line of block they can be reexcited. The wavefront of propagation 
circulates the smallest pathway possible around the conductive barrier. Functional 
conduction block can be rate dependent (Schuilenburg & Durrer 1973, Nattel 1999, Bian 
& Tung 2006).  
 
Abnormalities in Cx43 have been associated with conduction block in vivo. In the healing 
canine infarct model abnormally distributed Cx43 immunolabelling was present along the 
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lateral surfaces of cells in the infarct epicardial border zone. These changes extended 
through the full thickness of the surviving layer of cells and correlated with the site of the 
diastolic pathway of ventricular tachycardia circuits (Peters et al. 1997). This study is 
described in detail in Introduction chapter 1.6. It has been suggested that the 
lateralisation of Cx43 seen in the atria of aged dogs forms a barrier for the local current 
circuit leading to block (Koura et al. 2002). 
 
Due to their immortality and consistency over time, HL-1 cells make a good in vitro 
model for investigating intercellular and electrophysiological modulation. In this part of 
the thesis the HL-1 cell line was characterised as a model and used to investigate the 
relationship between different pacing rates, activation patterns and gap junctional 
distribution on atrial myocytes.  The hypotheses to be addressed were: 
1. Conduction velocities will correlate with gap junctional coupling and connexin 
expression. 
2. Areas of abnormal conduction will correlate with abnormal connexin distribution 
and expression. 
 
7.2 Characterisation and optimisation of Hl-1 activity  
 
7.2.1 Effect of different drop sizes 
 
Initially MEA plates were seeded to cover the entire surface of the MEA plate up to the 
edge of the ring with a confluent monolayer of cells. This is the normal way of seeding 
cells in general cell culture techniques. After multiple attempts to stimulate these cells by 
point and field stimulation using a variety of pacing protocols, including modulation of 
stimulus duration and amplitude, it was concluded that it was not possible to stimulate 
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the cells with this method of seeding. This could be due to the phenomenon of source 
and sink mismatch. During stimulation the cells above the stimulating electrode are 
directly excited and then serve as a source of electric charge for depolarizing 
neighbouring unexcited cells towards their excitation threshold. The unexcited cells 
constitute an electric sink (load) for the excited cells. For propagation to succeed, the 
excited cells must provide sufficient source charge to the unexcited cells to bring their 
membrane to excitation threshold (Kleber & Rudy 2004). If the entire surface of the 
MEA plate is seeded with cells, the sink is too large for a single electrode to provide 
enough source charge. To overcome the limitation that the electrode size and, therefore, 
the size of the source charge was fixed, I devised and optimised a method to seed the 
cells over a smaller region to decrease the size of the sink and remove the source and 
sink mismatch. This method was consistent and reproducible and, therefore, was used 
for the subsequent studies.  
 
The final optimised protocol is described in HL-1 Methods Chapter 4.4.2 where during 
passaging of cells from a T25 flask, after resuspension in 500 l Claycomb medium, a 
10 l drop of cells was seeded on the centre of the MEA plate and allowed to settle for 
30 minutes after which the plates were flooded with 500 l of supplemented Claycomb 
medium.  
 
In order to obtain this final protocol different drop sizes and dilutions were first 
investigated. Resuspension volumes of 100 to 1000 l were tested to investigate the 
effects of different dilutions of cells. Volumes of 100 l did not provide adequate 
coverage of all the electrodes. 1000 l led to an over confluent monolayer. The final 
dilution volume of 500 l was chosen as it allowed cells to be seeded at confluency 
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without being over-confluent. Electrical activity on the MEA plates for between 5 and 
50 l drops was then investigated to determine the optimal drop size to prevent source 
and sink mismatch and allow for stimulation to be successful. A 5 l drop did not extend 
over all electrodes. Drops above 25 l could not be stimulated. 10 l was found to show 
the most consistency in terms of ability to be stimulated. Figure 7.1 shows an example 
electrogram following successful stimulation. This is equivalent to seeding a 0.5cm2 
confluent monolayer.  
 
 
 
 
Figure 7.1 MEA recording with a 10 l drop of HL-1 cells with successful stimulation 
A clear extracellular electrogram response is seen after the stimulus artefact. Cells that could not be stimulated 
showed only a spike from the stimulation artefact and no cellular response. 
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7.2.2 Change in electrical activity over time in culture 
 
Recordings were taken every 24 hours after seeding to characterise the change in 
conduction velocity over time. To ensure consistency throughout plates all plates were 
paced at 3Hz (just above the intrinsic rate of 1-2Hz). When electrical activity was 
checked 24 hours after seeding, the cells could not be paced. Intrinsic activity was slow 
and isochronal mapping showed non-uniformity of activation pattern. This may be due 
to the time needed for the cells to recover from trypsinisation and for re-synthesis of 
proteins to occur. After 48 and 72 hours cells showed a conduction velocity of less than 
the maximal reached after 96 hours (5.3±0.3mm/s, 14.4±1,4mm/s and 24.3±1.6mm/s 
respectively). After 96 hours conduction velocity was 24.3±1.6mm/s and remained stable 
until 144 hours. After 168 hours some preparations could no longer be paced. Figure 7.2 
shows how conduction velocity changed over time after seeding. The maximum 
conduction velocities of the HL-1 cells are slow in comparison to primary mouse atrial 
myocytes in culture which have a conduction velocity in the region of 34±6 cm/sec 
(Beauchamp et al. 2006). 
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Figure 7.2 Conduction velocities during pacing every 24 hours after seeding 
After 24 hours cells could not be paced. After 48 and 72 hours conduction was slower than the maximal. After 
96 hours conduction velocity was 24.3±1.6mm/s and remained stable until 144 hours. After 168 hours some 
preparations could no longer be paced.  
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Isochronal maps of activation times at each electrode were drawn using MatLab (The 
MathsWorks) (Figure 7.3).  
 
 
 
Figure 7.3 Examples of activation maps over time 
Examples of A] An activation map of intrinsic activity 24 hours after seeding cells. Cells could not be paced as 
intrinsic activity was slow (time taken to cross the array was 180ms) and isochronal lines showed non-uniformity of 
activation pattern and B] An activation map of cells pace at 3Hz  from the bottome of the array 72 hours after 
seeding showing a uniform activation pattern but a conduction velocity slower than the maximal (time taken to 
cross the array was 100ms). Scale bars are in ms. 
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To allow consistency for subsequent studies plates were checked from 3 days post 
seeding onwards. Plates with a conduction velocity of 20mm/s or above were used for 
subsequent studies as this was the minimum conduction velocity during the stable 
period.  
7.3 Effects of Pacing 
 
7.3.1 Changes in conduction velocity with changes in pacing rates 
 
In order to investigate the effects of pacing on conduction velocity and induction of 
functional conduction block in the cell model, MEA plates were paced from just above 
the intrinsic rate to just below the point of loss of capture. The intrinsic rate of the cells 
was 1-2Hz and capture was lost above 8Hz. There was no change in conduction velocity, 
measured in a straight line from the point of pacing to the furthest point across the array, 
with any rate of pacing (3Hz 22.4±0.9, 4Hz 22.0±1.1, 5Hz 23.1±0.50, 6Hz 22.2±0.8, 
7Hz 22.9±1.1, 8Hz 22.3±1.0 mm/s, p=ns) (Figure 7.4). 
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Figure 7.4 Conduction velocities when cells are paced at different rates 
There was no change in conduction velocity, measured in a straight line from the point of pacing to the furthest 
point across the array, with any rate of pacing.  
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When capture was lost the current used as the pacing stimulus was increased to check if 
capture was regained; if it was regained the pacing was continued. Therefore, the final 
loss of capture was not due to sub-threshold stimulation, but due to the pacing stimulus 
occurring in refractory period. Hence the refractory period can be considered cycle 
length at the point of loss of capture. Loss of capture was at 9Hz, making the refractory 
period for HL-1 clone 6 cells 111ms. 
 
7.3.2 Changes in conduction velocity when pacing from different sides of the 
array 
 
Although anisotropy of conduction exists in intact myocardium, cells in culture are not 
elongated as in whole tissue. Therefore, the conduction velocity was measured while 
pacing just above the intrinsic rate from the middle of each side of the array. There was 
no difference in conduction velocity when pacing from any direction (Top 22.0±0.7, 
Bottom 22.9±0.5, Left 22.6±0.7, Right 22.4±0.9 mm/s, p=ns) (Figure 7.5).  
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Figure 7.5 Conduction velocities when pacing from different sides of the array 
Conduction velocity was measured while pacing just above the intrinsic rate from the middle of each side of the 
array. There was no difference in conduction velocity when pacing from any direction. 
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7.3.3 Changes in activation pattern  
 
Neither a change in pacing rates nor the direction from which pacing was applied had an 
effect on the pattern of activation across the area of the array (Figure 7.6). Activation 
waves spread evenly outwards from the point of stimulation.  
 
 
 
Figure 7.6 Example activation maps with pacing from different sides of the array with 
different pacing rates 
 A] A plate paced from the bottom of the array at 3Hz and B] A plate paced from the right side of the array at 
8Hz. Scale bars are in ms 
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7.4 Connexin distribution on MEA plates 
 
In order to correlate the pattern of activation with the distribution of Cx43 in the same 
cells, I devised a novel method of imunocytochemistry directly applied on the MEA plate 
after electrical recordings had been taken. This is described in Methods 4.4 and 4.5. After 
recording of electrical activity, cells were fixed and immunolabelled. The culture medium 
ring was then removed and a coverslip was mounted.  
 
Confocal images were taken for each interelectrode space (Figure 7.7). Due to the lack of 
elongation of the Hl-1 cells in culture, it was not possible to identify which areas of the 
membrane represented the intercalated disc-like region of close membranal interaction 
without the presence of a marker for the intercalated disc. Therefore Cx43 labelling was 
carried out in conjunction with labelling for the intercalated disc protein N-cadherin. The 
areas where N-cadherin resided were considered to be the intercalated disc region. The 
areas of colocalisation of Cx43 and N-cadherin were considered to be representative of 
Cx43 in functional gap junctions in the region of the intercalated disc and, therefore, 
expression in this location was quantified using ImageJ software.  
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Figure 7.7 Confocal images of Cx43 and N-cadherin labelling on MEA plates 
 A] Double labelling of Cx43 and N-cadherin superimposed onto a phase contrast image B] double labelling of 
Cx43 and N-cadherin. Cx43 is shown in red and N-cadherin is shown in bright green C] Calculated image of 
areas where Cx43 and N-cadherin are colocalised. Dark green depicts areas where both Cx43 and N-cadherin 
are localised. D] Graph to show quantification of colocalisation of Cx43 and N-cadherin at each inter-electrode 
space on the MEA 
 
7.5 Electrode specific correlation of electrical activity during pacing and connexin 
distribution 
 
I had hypothesised that areas of functional conduction block, induced with incremental 
increase in rate of pacing, would correlate with remodelling of Cx43 expression. 
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However, no functional block was seen with any pacing rate, therefore, there was no 
correlation of abnormal conduction, depicted by areas of functional block, with the Cx43 
expression in these cells. Cx43 expression was present in all cells. Figure 7.8 shows an 
example of an activation map and its corresponding map of Cx43 expression.  
 
 
 
Figure 7.8 Example of an activation map and its corresponding map of Cx43 expression.  
A] Activation map during pacing B] Map of the expression levels of Cx43 in the same cells.  
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7.6 Discussion 
 
7.6.1 Main findings 
 
In this part of the thesis I have devised and optimised a novel protocol for seeding HL-1 
cells on microelectrode array plates in a way that can be successfully stimulated so that 
the HL-1 cells can be used as a model to investigate propagation of electrical activity. I 
also modified the standard MEA plates so that the same cells from which electrical 
recordings have been taken can then be used to investigate cellular protein expression by 
immunohistochemistry so that structure and function can be correlated directly on the 
same preparation. This is a novel technique in that the structure and function in these 
preparations can be spatially correlated. The electrical activity of the HL-1 cells in culture 
over time, during pacing at different frequencies and from different sites has been 
characterised. All pacing protocols showed uniform conduction with no anisotropy or 
functional conduction block. As there were no rate dependent conduction disturbances, 
the expression of Cx43 did not correlate with any areas of block. 
 
7.6.2 Establishment of a novel method of recording data using the MEA system 
and immunolabelling of the same preparation 
 
The novel method of applying immunohistochemistry techniques to an MEA plate as 
described in section 7.4 allows simultaneous recording of electrical propagation and 
investigation of protein distribution. This current work has used this novel method to 
investigate the expression of Cx43 and to correlate this with conduction propagation. 
However, the same method could be applied to any protein of investigation. Previous 
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studies have identified that spatial correlation of protein expression and conduction 
abnormalities can lead to insight into the mechanisms of arrhythmogenesis in animal 
models (Peters et al. 1997). This current work provides a method to allow such 
correlations to be made in in vitro models and could, therefore, be applied in a novel way 
with techniques which are only possible in vitro for example in conjunction with small 
interfering RNA (siRNA) or patterned culture techniques.  
 
7.6.3 Effect of a change in pacing rate on conduction propagation in HL-1 
cardiomyocytes 
 
This current work showed no change in conduction velocity or induction of functional 
block by incrementally increasing the pacing rate, although this phenomenon has been 
previously described (Bian & Tung 2006). Therefore, to investigate the role of gap 
junctions as a cellular mechanism of functional block in this model, a different approach 
to induction of functional block would be needed. As well as by rapid pacing, functional 
block can be induced in other ways. Initiation of re-entry by a critically timed premature 
stimulus was first described by Allessie (Allessie et al. 1977) where the premature wave 
propagated into the areas with shorter refractory periods and was blocked in the 
direction where refractory periods were longer. The line of conduction block extended 
across the centre of the preparation. This method could be applied to the MEA plates. 
 
7.6.4 Effect of pacing from different sides of the array 
 
In this current work the cells were paced from different sites in the array to investigate 
whether there was any anisotropy of conduction. There was no difference in conduction 
velocities when pacing from any direction. Anisotropy in intact myocardium presents 
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itself due to the elongated shape of the myocytes and the presence of intercalated discs 
mainly at the ends of the cells. HL-1 cultured cells have a rounded shape with 
intercalated discs all around the cell membrane (see Figure 7.7). Therefore, the 
characteristics of intact myocardium which allow anisotropy to exist are not intrinsically 
present in the HL-1 cells. Previously it has been shown that cyclic mechanical stretch can 
induce cultured neonatal rat cardiomyocytes to acquire orientation and lead to 
polarisation of Cx43 protein (Salameh et al. 2010). This model has not yet been used to 
investigate conduction propagation in vitro. It should be possible to use this technique to 
induce orientation and polarisation of Cx43 in the HL-1 cells so that anisotropy of 
conduction could be investigated in this model.  
 
In conclusion, this part of the thesis has characterised the conduction properties of the 
HL-1 cell model and produced a novel method by which conduction propagation can be 
correlated with cellular protein distribution in the same preparation. Further work is 
necessary to use this model to investigate the role of structural gap junctional changes in 
abnormal conduction propagation.  
  
199 
Chapter 8: Results - The effects of 
pharmacological gap junction 
modulation in HL-1 cardiomyocytes 
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8.1 Introduction 
 
Pharmacological agents can modulate gap junctional intercellular communication either 
by uncoupling (increasing intercellular electrical resistance) or coupling (decreasing 
intercellular electrical resistance).  
 
8.1.1 Gap junction uncouplers 
 
Lipophilic agents such as heptanol, octanol, myristoleic acid, decaenoic acid or 
palmitoleic acid can act as uncouplers (Burt et al. 1991, Dhein et al. 1999). The 
mechanism of action of these drugs is most commonly explained by incorporation into 
the cell membrane lipid bilayer leading to impairment of the function of the gap 
junctional channels (Dhein 2004). Patch clamp studies with heptanol and neonatal rat 
cardiomyocytes suggested that the reduction in coupling is by a decrease in the open 
probability of the channels by acting on the structure of the lipid membrane (Takens-
Kwak et al. 1992). Oleic acid, myristoleic acid and palmitoleic acid have also been shown 
to have a similar action in cell culture (Burt et al. 1991, Hirschi et al. 1993). As the 
mechanism of action of these drugs is via interaction with the cell membrane and not by 
direct action on gap junctions, their action is non-specific and can inhibit other ion 
channels as well (Dhein 2004). Indeed, most pharmacological uncouplers, including 
heptanol and octanol, also inhibit ion channels (Takens-Kwak et al. 1992, Pappas et al. 
1996). Therefore, the use of these drugs in the study of the effects of gap junction 
modulation on conduction propagation is limited by confounding ion channel effects. 
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The glycyrrhetinic acid metabolites 18- -glycyrrhetinic acid and 18- -glycyrrhetinic acid 
have been shown to uncouple gap junction channels. 18- -glycyrrhetinic acid inhibits 
cell-to-cell coupling in rabbit arteries (Taylor et al. 1998, Chaytor et al. 1999). 18- -
glycyrrhetinic acid has been shown to reduce gap junctional electrical coupling in rat 
arteries (Allen et al. 2002). The molecular mechanism of uncoupling by glycyrrhetinic 
acid metabolites is still unknown, however, it has been suggested to involve 
phosphorylation or changes in the aggregation of connexin subunits (Dhein 2004). 
 
Carbenoxolone is a synthetic derivative of glycyrrhetinic acid and was previously licensed 
as a drug for the treatment of oesophageal ulceration and inflammation. It has been 
shown to decrease gap junction conductance between Cx43-transfected glioma cells 
independent of ion channel inhibition (Goldberg et al. 1996). It has also been 
demonstrated that carbenoxolone reduced conduction velocity in rabbit myocardium 
without alteration of ion currents (de Groot et al. 2003). In human right atria, 
carbenoxolone has been shown to slow wavefront propagation velocity without affecting 
refractoriness or electrogram morphology (Kojodjojo et al. 2006).  
 
8.1.2 Gap junction couplers 
 
In 1980, Aonuma and colleagues reported on a natural antiarrhythmic peptide found in 
bovine atrium, designated AAP (for antiarrhythmic peptide), which increased cell-to-cell 
coupling and synchronised clusters of spontaneously beating embryonic cultured 
myocardial cells (Aonuma et al. 1980). Subsequent mechanistic studies on a variety of 
cardiac tissue suggested that its antiarrhythmic effects are not mediated by ion channel 
effects (Argentieri et al. 1989). After an investigation of a series of AAP analogues, it was 
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found that AAP10 had the most potent action (Dhein et al. 1994). Work on isolated pairs 
of guinea pig myocytes determined the mechanism of action to be via reestablishment of 
gap junction intercellular communication (Muller et al. 1997). 
 
Rotigaptide is an analogue of AAP10. Both AAP10 and rotigaptide have been shown to 
reduce dispersion of epicardial potential duration and act against ischaemia-induced 
ventricular fibrillation (Grover & Dhein 2001). Similarly, rotigaptide was effective in 
enhancing gap junctional intercellular communication and preventing ventricular 
fibrillation in a canine model (Hennan et al. 2006).  
 
It is thought that AAPs might preferentially act on partially uncoupled cells. The positive 
effect of AAP10 on gap junction current in human cardiomyocytes was significantly 
enhanced in partially uncoupled cells in comparison to normally coupled cells (Hagen et 
al. 2009). Similarly, in acidosis-induced uncoupling, rotigaptide prevented conduction 
slowing, while it had no effect on conduction under control conditions (Eloff et al. 
2003). The positive effect of rotigaptide on atrial conduction was only detectable in atria 
undergoing metabolic stress (Haugan et al. 2005) or ischaemia-induced atrial fibrillation 
(Shiroshita-Takeshita et al. 2007).  
 
The molecular target for this class of compounds is still unknown. However it has been 
suggested that rotigaptide inhibits ischaemia-induced dephosphorylation of Ser297 and 
Ser368, which are considered important for the gating of Cx43 gap junction channels 
(Kjolbye et al. 2007).  
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In this part of the thesis the gap junctional modulators carbenoxolone, as an uncoupler, 
and rotigaptide, as a coupler, were used as tools to investigate the role of gap junctional 
intercellular communication on electrical propagation in HL-1 cardiomyocytes. The 
hypotheses to be addressed were: 
1. Administration of the gap junctional uncoupler, carbenoxolone, will lead to 
conduction slowing via a reduction in intercellular communication. 
2. Administration of the gap junctional coupler, rotigaptide, will lead to an increase 
in conduction velocity via enhancement of intercellular communication. 
 
8.2 Dose response for Carbenoxolone 
 
A dose response curve for carbenoxolone was made to assess the range of doses to use 
in subsequent studies. Cells were paced at 3Hz, a baseline reading was taken, and then 
incremental doses of 100, 200, 400 and 1000 M carbenoxolone were added for 10 
minutes each (Figure 8.1). Administration of 100 to 400 M carbenoxolone led to an 
increase in conduction delay across the array. A dose of 1000 M carbenoxolone led to 
complete block of conduction at 10 minutes and was therefore considered too high for 
further investigation.  
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Figure 8.1 Dose response curve for carbenoxolone after 10 minutes 
Administration of 100 to 400 M carbenoxolone caused an increase in conduction delay across the array. A dose 
of 1000 M carbenoxolone caused complete block of conduction at 10 minutes.  
 
8.3 Effects of carbenoxolone on electrical activity 
 
To investigate the effects of carbenoxolone on electrical activity, 100, 200 and 400 M 
carbenoxolone was added for up to two hours followed by one hour of washout as 
described in Methods section 4.6.1. All studies were undertaken with pacing at 3Hz. 
Conduction delay from the point of pacing to the electrode directly across the array was 
measured to assess the effect of carbenoxolone on gap junctional intercellular 
communication. The amplitude and duration of the activation complex of the 
extracellular electrogram was used to determine that there was no effect of 
carbenoxolone on ion channel activity. Conduction delay and amplitude and duration of 
the activation complex were calculated as described in Method section 4.4.4. For 
consistency of comparison, all subsequent data is shown as percentage change from 
baseline (time point 0) as each plate had a slightly different baseline, although the 
standard deviation was small, as described in section 7.3.1.  
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8.3.1 Effects of carbenoxolone on conduction delay 
 
Administration of 100 M carbenoxolone had no significant effect on conduction delay 
up to 120 minutes. A dose of 200 M carbenoxolone led to conduction slowing and 
400 M carbenoxolone led to conduction block at 120 minutes. Figure 8.2 shows 
example electrograms for each dose and time point.  
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Figure 8.2 Example electrograms with carbenoxolone administration 
A] Administration of 100 M carbenoxolone had no effect on conduction delay up to 120 minutes. B] A dose of 
200 M carbenoxolone led to conduction slowing and C] A dose of 400 M carbenoxolone led to conduction block 
at 120 minutes. The initial spike at 0ms is the stimulation artefact. 
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200 M carbenoxolone increased conduction delay both at 60 minutes (197.1±61.31%, 
p<0.001) and 120 minutes (249.0±80.05%, p<0.001). 400 M carbenoxolone increased 
the delay at 60 minutes (537.1±103.4%, p<0.001) in two preparations while two 
preparations showed conduction block and at 120 minutes blocked conduction in all 
preparations. After 60 minutes washout, conduction velocities for all doses were not 
significantly different to baseline (Figure 8.3).  
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Figure 8.3 Percentage change in conduction delay compared to baseline 
100 M carbenoxolone had no effect on conduction delay. 200 M carbenoxolone increased conduction delay both 
at 60 minutes and 120 minutes. 400 M carbenoxolone increased the delay at 60 minutes in two preparations 
while two preparations showed conduction block and at 120 minutes blocked conduction in all preparations. After 
60 minutes washout, conduction velocities for all doses were not significantly different to baseline.  
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8.3.2 Effects of carbenoxolone on activation complex amplitude 
 
There was no significant difference in the amplitude of the activation complex at any 
dose or time point (Figure 8.4).  
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Figure 8.4 Percentage change in activation complex amplitude 
There was no statistically significant difference in the amplitude at any dose or time point.  
 
8.3.3 Effects of carbenoxolone on activation complex duration 
 
There was no significant effect on activation complex duration with a dose of 100 M 
carbenoxolone. 200 M carbenoxolone had no effect on the duration of the activation 
complex at 60 minutes but increased the duration of the activation complex by 120 
minutes (50.3±6.32%, p<0.05). At a dose of 400 M there was no statistically significant 
change in the duration of the activation complex, although there was a trend towards an 
increase at 60 minutes, no activation complex duration was measured at 120 minutes as 
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there was block. All changes were completely reversed after 60 minutes washout (Figure 
8.5).  
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Figure 8.5 Percentage change in activation complex duration 
There was no significant effect on activation complex duration with a dose of 100 M carbenoxolone. 200 M 
carbenoxolone had no effect on the duration of the activation complex at 60 minutes but increased the duration of 
the activation complex by 120 minutes. At a dose of 400 M there was no statistically significant change in the 
duration of the activation complex. All changes were completely reversed after 60 minutes washout.  
 
8.3.4 Effects of carbenoxolone on activation patterns 
 
To investigate the pattern of activation, isochronal maps were drawn for every 
preparation apart from when there was block. Although conduction slowing occurred on 
carbenoxolone administration as described in 8.3.1, there was no change in activation 
pattern apart from a crowding of isochronal lines consistent with slowing (Figure 8.6).  
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Figure 8.6 Examples of activation maps showing baseline and on administration of 
carbenoxolone 
A] Baseline activation map B] activation map after administration of 200 M carbenoxolone for 60 minutes. 
Although conduction slowing occurred on carbenoxolone administration there was no change in activation pattern 
apart from a crowding of isochronal lines consistent with slowing. 
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8.4 Effects of carbenoxolone on Cx43 expression 
 
Western blotting was carried out as described in Methods section 4.7. Quantification of 
junctional docked (D), non-junctional undocked (UD) and total (D+UD) was carried out 
using all (phosporylated and non-phosphorylated) bands, to investigate whether the 
mechanism of action of carbenoxolone was by a change in the aggregation of connexin 
subunits. Quantification was then carried out for the phosphorylated band separately, to 
investigate whether the mechanism of action was by a change in phosphorylation states 
(Dhein 2004). An example blot is shown in Figure 8.7.  
 
 
Figure 8.7 An example of a blot for Cx43 and its corresponding Coomassie 
A] An example of a Western blot. Each sample is loaded as docked (D), undocked (UD) and total sample and 
takes three lanes. B] The corresponding Coomassie showing the actin and myosin bands used for correction of 
protein loading. Samples were loaded under blinded conditions and, therefore, are in a random order. 
 
8.4.1 Effects of carbenoxolone on overall Cx43 expression 
 
Administration of 200 and 400 M carbenoxolone for up to 120 minutes then for 60 
minutes washout had no effect on the overall expression of Cx43 (Figure 8.8). To assess 
whether carbenoxolone administration had modulated the aggregation of Cx43 subunits, 
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the expression levels of docked and undocked Cx43 after carbenoxolone administration 
was compared. There was no significant change in expression of docked and undocked 
Cx43 with carbenoxolone administration.   
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Figure 8.8 Docked, undocked and total Cx43 expression levels with carbenoxolone 
A] Cx43 expression levels with administration of 200 M carbenoxolone and B] Cx43 expression levels with 
administration of 400 M carbenoxolone. There was no change with any dose at any timepoint.  
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 8.4.2 Effects of carbenoxolone on phosphorylation states of Cx43 
 
To assess if carbenoxolone administration had an effect on the phosphorylation state of 
Cx43, the phosphorylated top band (P2) was quantified separately. A ratio of this against 
quantification of all bands provided information on the proportion of phosphorylated 
Cx43 protein. No significant difference was seen at any time point or with any dose of 
carbenoxolone (Figure 8.9).  
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Figure 8.9 Ratio of phosphorylated Cx43 against total with carbenoxolone administration   
No significant difference was seen at any time point or with any dose of carbenoxolone. 
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8.5 Visual analysis of the effects of carbenoxolone 
 
As 400 M carbenoxolone produced conduction block, 800 M carbenoxolone can be 
considered a supra-maximal dose. The effects of 800 M carbenoxolone were assessed 
visually in a culture flask (Figure 8.10). At baseline there was a confluent cultured cell 
monolayer and cells were contracting in synchrony. By 30 minutes after carbenoxolone 
administration the cells quickly became physically detached from each other and from 
the surface of the flask. Within two hours many cells had decreased in size and were no 
longer connected to any other cells. Dead cells, depicted by small circular bodies floating 
in the medium, were clearly visible. After four hours very few cells remained attached to 
the base of the flask. This suggests that carbenoxolone has had an effect on the 
intercellular adhesion. This was assessed quantitatively using a trypan blue assay. There 
was increase in percentage of dead cells calculated by the trypan blue assay after 4 hours 
of incubation with 800 M carbenoxolone (93.2±10.6%, n=8) compared with control 
(11.1±4.6%, p=0.039, n=12) (Figure 8.10). 
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Figure 8.10 Cell death in HL-1 cells over time with 800 M carbenoxolone administration 
A] Trypan blue of control cells with few blue dead cells B] Trypan blue of cells treated with 800mM 
carbenoxolone for 4 hours with only one surviving cell (red arrow) C] Graph to show percentage of dead cells after 
carbenoxolone administration 
8.6 Rotigaptide 
 
To investigate the effects of rotigaptide on electrical activity 50, 100, 200 and 500nM 
rotigaptide was added for up to 24 hours as described in Methods section 4.6.2. These 
doses were chosen as 50nM rotigaptide has previously been shown to increase cellular 
dye transfer in HL-1 cells (Clarke et al. 2006). All studies were undertaken with pacing at 
3Hz. Conduction delay was measured to assess the effect of rotigaptide on gap junctional 
intercellular communication. There was no change in conduction delay with up to 
500nM administered for up to 24 hours (Figure 8.11). The dose used in this study is 10 
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times higher than previous studies; therefore, a change should be detected, if one was to 
occur. 
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Figure 8.11 Example of the raw data traces with rotigaptide administration 
Administration of 500nM rotigaptide showed no change after 24 hours compared to the baseline.  
 
8.7 Discussion 
 
8.7.1 Main findings 
 
The main findings of this part of the thesis are that carbenoxolone administration leads 
to progressive conduction slowing and ultimately leads to conduction block in HL-1 
cardiomyocytes with doses of 200 to 400 M over 120 minutes. The morphology of the 
extracellular electrogram in terms of duration and amplitude of the activation complex 
remain unchanged (except for an increase in duration with 200 M carbenoxolone after 
120 minutes). These changes are reversible with washout. There is no change in pattern 
of activation with carbenoxolone administration. There is no change in functional Cx43 
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docked (in gap junctional channels), undocked Cx43 (not in gap junctional channels) or 
overall Cx43 expression with doses that show conduction slowing either for the total 
expression of Cx43 or for the ratio of phosphorylated to total Cx43. Visual assessment 
of the effect of carbenoxolone showed that a supra-maximal dose can reduce cell 
viability. Rotigaptide has no effect on HL-1 cells in the absence of stress. 
 
8.7.2 The effects of carbenoxolone on HL-1 cells 
 
This current work shows that carbenoxolone administration leads to progressive 
conduction slowing and ultimately to conduction block in HL-1 cardiomyocytes. There 
was little change in electrogram morphology with carbenoxolone administration in HL-1 
cells suggesting that the conduction slowing was independent of ion channel inhibition.  
These findings are consistent with previous studies (de Groot et al. 2003, Kojodjojo et al. 
2006).  
In this current work no changes were seen in the expression of phosphorylated Cx43. It 
has previously been suggested that, although the molecular mechanism of the 
glycyrrhetinic acid metabolites is still unknown, it could involve phosphorylation or 
changes in the aggregation of connexin subunits (Dhein 2004). However, experimental 
evidence from this work and previous studies do not support this hypothesis. In bovine 
aortic endothelial cells, carbenoxolone administration was shown to reduce gap 
junctional communication and increase Cx43 expression (Sagar & Larson 2006). The 
authors went on to suggest that this was a feedback mechanism for Cx43 expression. In 
another study carbenoxolone administration has been shown to have no effect on 
phosphorylation states or expression of Cx43 in neuronal cells (Bani-Yaghoub et al. 
1999).  This current work shows no change in the proportion of Cx43 present in docked 
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junctional channels, which is contradictory to a previous study in glioma cells that 
suggested an alteration in connexon particle packing (Goldberg et al. 1996). In this 
current work Cx43 expression remains unchanged with carbenoxolone administration 
suggesting that the mechanism of action is not by a change in Cx43 expression but by a 
different process, possibly involving a conformational change or by direct ligand binding. 
Therefore, although the effects of carbenoxolone on electrophysiological parameters are 
well established, and concur with the results of this current work, the mechanism of 
action is still unclear and further study is necessary. Nevertheless, carbenoxolone remains 
a useful tool in the investigation of gap junctional coupling.  
 
8.7.3 The effect of rotigaptide on HL-1 cells 
 
Rotigaptide administration had no effect on HL-1 cells in this current work. Previous 
studies have suggested that antiarrhythmic peptides might preferentially act on partially 
uncoupled cells, for example during acidosis-induced uncoupling (Eloff et al. 2003), 
metabolic stress (Haugan et al. 2005) or ischaemia (Shiroshita-Takeshita et al. 2007). In 
this current work the HL-1 cells did not undergo any process to induce stress. Previous 
dual patch clamp studies with these cells had shown a high proportion of channels in the 
closed state (unpublished work of Dr T Desplantez). Therefore, it was thought that any 
further induction of stress was unnecessary. However, as no change in conduction was 
seen on administration of rotigaptide without extra stress induction this should be 
explored further. This could be done by changing the pH of the medium leading to 
acidosis, or by bubbling the medium with nitrogen to remove the oxygen and induce 
ischaemia. 
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In conclusion, this part of the thesis has confirmed the action of carbenoxolone on 
conduction slowing without affecting electrogram morphology, except at a high dose. 
The cellular mechanism of action of carbenoxolone remains unclear. No change was 
seen on administration of rotigaptide to Hl-1 cells. This could be due to the fact that 
these cells are not naturally in a state of metabolic stress.  
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Chapter 9: Discussion 
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9.1 Summary of findings 
 
In this thesis I examined the relationship between atrial electrical remodelling and 
structural changes, including the expression and distribution of gap junctional proteins, 
in the goat model of AF in which the “second factor(s)” had already been shown to 
operate. I used the AT1 receptor antagonist candesartan as a tool to investigate if its 
administration would attenuate the electrical and structural remodelling that occurs in the 
goat model of AF, thereby giving insight into the role of the angiotensin system in the 
development of stability in AF. Subsequently, I used the HL-1 cell line as a tool to 
correlate electrical abnormalities, connexin remodelling and cell to cell connectivity.  I 
investigated the relationship among different pacing rates, activation patterns and gap 
junctional distribution in cultured atrial myocytes.  I used the gap junctional modulators 
carbenoxolone as an uncoupler and rotigaptide as a coupler to investigate the role of gap 
junctional intercellular communication on electrical propagation in HL-1 cardiomyocytes. 
 
9.1.1 Goat AF model 
 
The results from the goat AF model showed that AF electrical remodelling includes an 
increase in the stability of atrial refractoriness, an increase in the heterogeneity of local 
conduction velocities in the absence of overall conduction changes, an increase in 
electrogram fractionation and an increase in the complexity of activation patterns. 
Concurrently, in the same model, structural remodelling includes lateralisation of the gap 
junctional protein Cx43 and a change in the expression of Cx43 in the right atria, loss of 
label and introduction of heterogeneity of distribution of Cx40, myolysis and 
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hypertrophy via an increase in cell size. Correlation of the electrical and structural 
remodelling suggests that these happen simultaneously. 
 
Clinical data from patients with AF concur with these current data, in most respects, 
which suggest this is an accurate model of AF. However, in human studies, changes in 
atrial conduction velocity in patients with AF have been conflicting. P wave duration has 
been used as a surrogate marker of atrial conduction and has been found to be prolonged 
in patients with AF (Yamagata et al. 1999). However, a study of patients with paroxysmal 
lone AF showed no change in conduction velocity (Zimmermann et al. 1998). The work 
in this thesis showed an increase in the heterogeneity of local conduction velocities in the 
absence of overall conduction changes. An increase in fractionation of electrograms was 
also seen, as previously described in patients with AF (Tai et al. 2001).  
 
Previous studies of patients with AF suggest that connexin remodelling predominantly 
involves changes in expression and distribution of Cx40 (Dupont et al. 2001, 
Kanagaratnam et al. 2004). The work in this thesis confirms the role of Cx40 
distribution, but shows that Cx43 remodelling also occurs. In this current work no 
increase in fibrosis was seen. However, studies of patients with AF suggest that fibrosis 
plays a role in AF only in the presence of ventricular dysfunction or other underlying 
pathologies (Ohtani et al. 1995, Xu et al. 2004, Khan & Sheppard 2006). The goat model 
used in this thesis is a model of lone AF, which may explain the lack of fibrosis. 
Therefore, there are some differences between this model and the clinical context which 
must be kept in mind when considering the clinical implications of this work.  
 
The work in this thesis identified for the first time that Cx43 remodelling occurs during 
AF. There is an increase in the expression of Cx43 in the right atria between 1 and 2 
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months of AF and not between control and 1 month AF. This is consistent with the 
theory that connexin remodelling is involved in the “second factor” after the initial 
electrical remodelling has occurred. It has been suggested that enhanced myolysis and 
perinuclear accumulation of glycogen are responsible for increasing AF stability (Ausma 
et al. 1997). The work in this thesis has demonstrated the presence of myolysis in this 
goat model of AF.  Myolysis is thought to occur as a result of prolonged loss of 
contractile activity, which may lead to increased passive stretch, which in turn may lead 
to an increase in cell size (Ausma et al. 1997). This process delays recovery after 
cardioversion in humans (Van Gelder et al. 1993, Manning et al. 1994). This current 
work has shown that cell size increases in this goat model. Therefore, this thesis provides 
evidence to support the theory that an increase in cell size and myolysis influence stability 
of AF and are involved in the “second factor”. 
 
Despite evidence that the AT1 receptor is inhibited by oral candesartan in this current 
model, measured by a reduction in blood pressure, treatment with candesartan had no 
effect on atrial electrical remodelling or the increased stability of AF. However, there was 
a reduction in the lateralisation of Cx43 seen with increased duration of AF. This 
suggests that although there is no attenuation of electrical remodelling, candesartan has 
an effect on the structural remodelling occurring in AF. In other animal models (Li et al. 
1999, Nakashima et al. 2000, Shinagawa et al. 2002) the angiotensin system has been 
shown to play a role in the electrical remodelling in AF. However these models showed 
that that the mechanism of attenuating atrial arrhythmogensis by blockade of the action 
of angiotensin II may require the presence of underlying ventricular dysfunction. This is 
supported by clinical evidence that the greatest benefit of angiotensin system blockade is 
in those patients with structural heart disease (Pedersen et al. 1999) and when patients in 
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whom significant structural heart disease or hypertension had been excluded AT1 
antagonism was ineffective in reducing AF occurrence (Madrid et al. 2004).  
 
9.1.2 HL-1 model 
 
In the work for this thesis I have devised and optimised a protocol for seeding HL-1 
cells on MEA plates for investigating conduction propagation. I have also devised a 
novel method which allows the investigation of cellular protein expression, by 
immunohistochemistry on the MEA plates, so that structure and function can be 
correlated directly in the same preparation. The electrical activity of the HL-1 cells in 
culture over time, during pacing at different frequencies and from different sites has been 
characterised. HL-1 cells show a homogenous pattern of activation at any pacing rate 
with no anisotropy or functional conduction block. As there were no rate dependent 
conduction disturbances, the expression of Cx43 did not correlate with any areas of 
block.  
 
The work in this thesis has shown that treatment with carbenoxolone leads to 
progressive conduction slowing in Hl-1 cardiomyocytes. There is no change in pattern of 
activation with carbenoxolone administration. The morphology of the extracellular 
electrogram in terms of duration and amplitude of the activation complex remain 
unchanged (except for an increase in duration with 200 M carbenoxolone after 120 
minutes). These changes are reversible with washout. This current work concurs with 
previous work which shows that carbenoxolone administration leads to a decrease in gap 
junction conductance between Cx43-transfected glioma cells independent of ion channel 
inhibition (Goldberg et al. 1996) and a reduced conduction velocity in rabbit 
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myocardium without alteration of ion currents (de Groot et al. 2003). Clinical data in the 
human right atria also concurs with this study, showing carbenoxolone slows wavefront 
propagation velocity without affecting refractoriness or electrogram morphology 
(Kojodjojo et al. 2006).  
 
At the same doses and time points after administration of carbenoxolone at which 
conduction slowing is seen, there is no change in docked, undocked or overall Cx43 
expression, either for the total expression of Cx43 or for the ratio of phosphorylated to 
total Cx43. This work suggests that although the action of carbenoxolone is gap junction 
specific, the mechanism of action is not via modulation of Cx43 expression or 
phosphorylation. Further work could be carried out to determine the mechanism of 
action.  
 
Although carbenoxolone can no longer be prescribed in the UK, it remains a useful drug 
for use as a research tool to investigate the role of gap junctions in conduction 
propagation and abnormalities by providing a way to modulate gap junctional coupling 
without affecting ion channels.  
 
This current work showed that rotigaptide administration had no effect on HL-1 cells. 
Previous studies have suggested that antiarrhythmic peptides might preferentially act on 
partially uncoupled cells (Eloff et al. 2003, Haugan et al. 2005, Shiroshita-Takeshita et al. 
2007). In this current study the HL-1 cells did not undergo any process to induce stress. 
As no change in conduction was seen without extra stress induction, this should be 
explored further.  
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9.2 Clinical relevance of findings  
 
AF becomes more persistent with time, as this thesis and other studies have shown. The 
inconsistencies in timescales of electrical remodelling and development of persistent AF 
have lead to the theory that a “second factor” may exist which influences the overall 
remodelling process. The self-perpetuation of AF in this goat model is accompanied by 
progressive structural changes in atrial connexin distribution, consistent with the 
hypothesis that AF-induced connexin remodelling is a “second factor” involved in the 
self-perpetuating process. Therefore, there is a justification in investigating novel 
therapies directed at influencing gap junction remodelling as they may have a future role 
in the clinical management of patients with AF.  Although angiotensin system 
modulation plays a role in pharmacological therapy of AF, this thesis concurs with 
previous work that suggests that this class of drugs will only be effective in certain 
groups of patients, namely those who also have ventricular dysfunction.  
 
It has been hypothesised that control of conduction velocities by the use of gap junction 
modulators could lead to attenuation of conduction abnormalities. In this thesis the use 
of these drugs in the HL-1 cell model has given an insight into the mechanism by which 
these drugs act and contributed to the first step in investigating their therapeutic 
relevance.  
 
9.3 Strengths and limitations 
 
The work in this thesis used a well established burst pace goat model which has 
previously been shown to be a representative model of AF in humans (Wijffels et al. 
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1995, Wijffels et al. 1997, Todd et al. 2004). In some models AF is induced by secondary 
mechanisms, for example by creating mitral regurgitation (Cox et al. 1991) or sterile 
pericarditis (Kumagai et al. 1997). In this current work the goats used began the study in 
sinus rhythm, therefore, they had no known previous pathological substrate for AF. This 
suggests that any changes observed most likely represent changes due to atrial fibrillation 
and not due to confounding factors of other pathologies.  
 
The goats in this work were in sinus rhythm with structurally normal hearts and were a 
model of lone AF due to the fact that this model is induced by burst pacing alone.  
Therefore, one limitation of this model is that it does not represent the pathological 
substrate encountered in clinical AF due to specific causes. The study protocol may have 
introduced a confounding factor as placement of the pacemaker leads may lead to 
scarring of the atria thereby creating a substrate for AF.  
 
Although correlations of structural and electrical factors were made, the tissue taken was 
from the same general region and not from directly under the electrodes as in the canine 
healing infarct model (Peters et al. 1997). This would have been a more accurate way to 
correlate the data, but would have been practically difficult.  
 
The HL-1 cell model provides an immortal cardiomyocyte line which retains a 
differentiated cardiac myocyte phenotype and maintains contractile activity over 
indefinite passages (Claycomb et al. 1998). This provides advantage over primary 
cultured cells which may be subject to progressive changes in phenotype, as the cells 
become less differentiated state over time in culture, limiting their uses (White et al. 
2004).  
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However, the HL-1 cell line lacks anisotropy due to a lack of a structured cell shape and 
a distribution of gap junctions along the cell perimeter compared with cells in vivo in 
which the gap junctions are localised at the intercalated disc. This is a simplification 
which must be kept in mind when considering the role of conduction propagation 
abnormalities and connexin expression in this model.  
 
Arrhythmias are multifactorial in origin and may involve gap junctional remodelling 
alongside other factors for example fibrosis in AF (Verheule et al. 2010). These processes 
may occur via the interaction of different cell types, for examples myocytes with 
fibroblasts. Therefore, study of a cell line provides consistency of cell type but does not 
allow the investigation of the interaction of different cells types which are found in vivo. 
For this reason results obtained in vitro must be carefully interpreted and validated by 
studies in vivo. 
 
9.4 Future directions 
 
The goat burst pace model of AF has been shown to be a useful tool in the investigation 
of the second factors of AF. However, in this thesis no effect was seen with AT1 
receptor blockade. The possible reason for this has been identified as the lack of 
ventricular dysfunction. Future studies could involve using an adaptation of this model to 
incorporate ventricular dysfunction.  
 
This thesis has identified gap junction remodelling to be involved in the “second factor”. 
Specific gap junctional modulators are now available and could be used to investigate if 
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administration of these drugs could lead to attenuation of the gap junctional changes and, 
therefore, the stability of AF in this model.  
 
This thesis has identified the HL-1 cells and the MEA system as useful tools in the 
investigation of conduction propagation and gap junction abnormalities. No conduction 
block was seen in the HL-1 cells with a change in pacing rate. However, the pacing 
protocol could be modulated, for example to include long term rapid electrical 
stimulation, so that this model might mimic the electrophysiological changes seen in AF. 
This model could then be used to further characterise the gap junctional remodelling that 
occurs in AF. The lack of anisotropy in these cells makes this model different from intact 
myocardium. The cells could be subjected to patterned growth, for example by 
mechanical stretch or by patterned seeding to induce anisotropy, which would make it a 
more accurate model of in vivo myocardium. 
 
Although this thesis investigated the role of gap junction uncouplers in conduction 
abnormalities, the HL-1 model was not suitable for investigation of the role of the gap 
junctional coupler rotigaptide due to the lack of stress induction. The model could be 
subjected to stress in order to investigate this further. This could be done by changing 
the pH of the medium leading to acidosis, or by bubbling the medium with nitrogen to 
remove the oxygen and induce ischaemia. The work from this thesis concurs with 
previous evidence that carbenoxolone is a useful tool in the investigation of the role of 
gap junctions in conduction propagation as its action is specific on gap junctions and 
does not affect ion channels. However, this is measured using surrogates of ion channel 
activity, for example electrogram morphology. The new upgraded MEA systems allow 
for dual MEA recording concurrently with patch clamp work. This would provide a way 
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of directly investigating the effect of gap junctional modulators on both conduction 
propagation and ion channel activity at the same time.   
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9.5 Conclusions 
 
This thesis provides an insight into the role of gap junctions in conduction propagation 
in both the intact myocardium in an animal model of AF and in an in vitro cell model. 
The goat model identified for the first time the role of Cx43 in AF and its involvement in 
“second factor”. Using the Hl-1 model this thesis has contributed to the understanding 
of gap junctional pharmacology. Therefore, this thesis provides an argument for targeting 
gap junctional modulation in future antiarrhythmic therapies.  
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